Raras
Buscar doenças, sintomas, genes...
Doença da fosforilação oxidativa mitocondrial
ORPHA:223713CID-11 · 5C53.2DOENÇA RARA

Distúrbio multissistêmico com manifestações variáveis ​​resultante de um defeito no sistema de fosforilação oxidativa mitocondrial (OXPHOS).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Distúrbio multissistêmico com manifestações variáveis ​​resultante de um defeito no sistema de fosforilação oxidativa mitocondrial (OXPHOS).

Publicações científicas
4.061 artigos
Último publicado: 2026 Apr 16
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
181 sintomas
💪
Músculos
86 sintomas
🦴
Ossos e articulações
81 sintomas
👁️
Olhos
74 sintomas
❤️
Coração
60 sintomas
🫃
Digestivo
53 sintomas

+ 542 sintomas em outras categorias

Características mais comuns

Neuropatia sensorimotora
Distonia da perna
Marcha na ponta dos pés
Calcâneo proeminente
Dilatação dos ventrículos laterais
Contratura congênita do pé
1319sintomas
Sem dados (1319)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 1319 características clínicas mais associadas, ordenadas por frequência.

Neuropatia sensorimotoraSensorimotor neuropathy
Distonia da pernaLeg dystonia
Marcha na ponta dos pésTip-toe gait
Calcâneo proeminenteProminent calcaneus
Dilatação dos ventrículos lateraisDilation of lateral ventricles

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1
Total histórico4.061PubMed
Últimos 10 anos200publicações
Pico2026191 papers
Linha do tempo
2025Hoje · 2026🧪 2012Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

82 genes identificados com associação a esta condição.

SLC25A4ADP/ATP translocase 1Disease-causing germline mutation(s) inModerado
FUNÇÃO

ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (PubMed:21586654, PubMed:27693233, PubMed:23173940, PubMed:30046662). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By si

LOCALIZAÇÃO

Mitochondrion inner membraneMembrane

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 2

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
563.9 TPM
Coração - Átrio
428.0 TPM
Músculo esquelético
370.5 TPM
Cérebro - Hemisfério cerebelar
138.9 TPM
Esôfago - Muscular
110.1 TPM
OUTRAS DOENÇAS (5)
mitochondrial DNA depletion syndrome 12B (cardiomyopathic type), autosomal recessivemitochondrial DNA depletion syndrome 12A (cardiomyopathic type), autosomal dominantprogressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2autosomal dominant progressive external ophthalmoplegia
HGNC:10990UniProt:P12235
MRPS16Small ribosomal subunit protein bS16mCandidate gene tested inModerado
LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationMitochondrial ribosome-associated quality controlMitochondrial translation initiationMitochondrial translation elongation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 2

A mitochondrial disease resulting in fatal neonatal metabolic acidosis with agenesis of the corpus callosum.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
88.3 TPM
Fibroblastos
87.9 TPM
Músculo esquelético
55.4 TPM
Glândula adrenal
53.9 TPM
Testículo
49.9 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation defect type 2
HGNC:14048UniProt:Q9Y3D3
MT-TL2Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (3)
mitochondrial diseasematernally-inherited progressive external ophthalmoplegiaalternating hemiplegia of childhood
HGNC:7491
MT-ND5NADH-ubiquinone oxidoreductase chain 5Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:15250827). Essential for the catalytic activity and assembly of complex I (PubMed:15250827)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Respiratory electron transportComplex I biogenesisMitochondrial translation terminationMitochondrial protein degradation
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (5)
mitochondrial diseaseMELAS syndromematernally-inherited Leigh syndromeMERRF syndrome
HGNC:7461UniProt:P03915
COX16Cytochrome c oxidase assembly protein COX16 homolog, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Required for the assembly of the mitochondrial respiratory chain complex IV (CIV), also known as cytochrome c oxidase (PubMed:29355485, PubMed:29381136, PubMed:33169484). Promotes the insertion of copper into the active site of cytochrome c oxidase subunit II (MT-CO2/COX2) (PubMed:29355485, PubMed:29381136). Interacts specifically with newly synthesized MT-CO2/COX and its copper center-forming metallochaperones SCO1, SCO2 and COA6 (PubMed:29381136). Probably facilitates MT-CO2/COX2 association w

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 22

An autosomal recessive mitochondrial disorder characterized by hypertrophic cardiomyopathy, encephalopathy, fatal lactic acidosis, and isolated complex IV deficiency.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 22mitochondrial complex IV deficiency, nuclear-type
HGNC:20213UniProt:Q9P0S2
TSFMElongation factor Ts, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Associates with the EF-Tu.GDP complex and induces the exchange of GDP to GTP. It remains bound to the aminoacyl-tRNA.EF-Tu.GTP complex up to the GTP hydrolysis stage on the ribosome. Participates in mitochondrial translation (PubMed:27677415)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial translation elongation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 3

A mitochondrial disease resulting in severe metabolic acidosis with encephalomyopathy or with hypertrophic cardiomyopathy. Patients show a severe defect in mitochondrial translation leading to a failure to assemble adequate amounts of three of the oxidative phosphorylation complexes.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
36.0 TPM
Fibroblastos
27.0 TPM
Linfócitos
25.1 TPM
Testículo
23.2 TPM
Cérebro - Hemisfério cerebelar
22.7 TPM
OUTRAS DOENÇAS (1)
fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3
HGNC:12367UniProt:P43897
TMEM126ATransmembrane protein 126ACandidate gene tested inTolerante
FUNÇÃO

Protein required for the cotranslational protein quality control in the inner membrane of the mitochondria (PubMed:38199007). Associates with newly synthesized polypeptides and may act as a chaperone that cooperates with OXA1L for the insertion of newly synthesized mitochondrial proteins into the inner membrane (PubMed:38199007). Required for the assembly of the ND4 module of mitochondrial complex I (PubMed:33879611, PubMed:33882309)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex I biogenesis
MECANISMO DE DOENÇA

Optic atrophy 7 with or without auditory neuropathy

A hereditary condition that features progressive visual loss in association with optic atrophy. Atrophy of the optic disk indicates a deficiency in the number of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. OPA7 is an autosomal recessive juvenile-onset optic atrophy characterized by severe bilateral deficiency in visual acuity, optic disk pallor, and central scotoma. Some patients manifest hearing loss.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
71.7 TPM
Fibroblastos
68.9 TPM
Testículo
67.7 TPM
Coração - Ventrículo esquerdo
48.5 TPM
Artéria coronária
48.2 TPM
OUTRAS DOENÇAS (1)
autosomal recessive optic atrophy, OPA7 type
HGNC:25382UniProt:Q9H061
MRPS7Small ribosomal subunit protein uS7mCandidate gene tested inTolerante
LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationMitochondrial ribosome-associated quality controlMitochondrial translation initiationMitochondrial translation elongation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 34

An autosomal recessive disorder caused by mitochondrial dysfunction and combined respiratory chain deficiencies of complexes I, III and IV. Clinical manifestations are variable and include congenital sensorineural deafness, lactic acidemia, and progressive hepatic and renal failure.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
62.5 TPM
Linfócitos
62.1 TPM
Fibroblastos
52.5 TPM
Coração - Ventrículo esquerdo
49.0 TPM
Esôfago - Mucosa
47.1 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation deficiency 34
HGNC:14499UniProt:Q9Y2R9
MT-TVCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (2)
mitochondrial diseasematernally-inherited Leigh syndrome
HGNC:7500
MT-ND3NADH-ubiquinone oxidoreductase chain 3Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:25118196). Essential for the catalytic activity of complex I (PubMed:25118196)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial translation termination
MECANISMO DE DOENÇA

Leigh syndrome

An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia.

OUTRAS DOENÇAS (4)
mitochondrial diseasematernally-inherited Leigh syndromeLeber plus diseasemitochondrial complex I deficiency
HGNC:7458UniProt:P03897
MTO15-taurinomethyluridine-[tRNA] synthase subunit MTO1, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Component of the GTPBP3-MTO1 complex that catalyzes the 5-taurinomethyluridine (taum(5)U) modification at the 34th wobble position (U34) of mitochondrial tRNAs (mt-tRNAs), which plays a role in mt-tRNA decoding and mitochondrial translation (PubMed:29390138, PubMed:33619562). Taum(5)U formation on mammalian mt-tRNA requires the presence of both GTPBP3-mediated GTPase activity and MTO1 catalytic activity (PubMed:29390138)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
tRNA modification in the mitochondrion
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 10

An autosomal recessive disorder resulting in variable defects of mitochondrial oxidative respiration. Affected individuals present in infancy with hypertrophic cardiomyopathy and lactic acidosis. The severity is variable, but can be fatal in the most severe cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
8.2 TPM
Cervix Ectocervix
7.8 TPM
Cervix Endocervix
7.7 TPM
Baço
7.5 TPM
Linfócitos
7.5 TPM
OUTRAS DOENÇAS (1)
mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency
HGNC:19261UniProt:Q9Y2Z2
MT-CO3Cytochrome c oxidase subunit 3Candidate gene tested inDesconhecido
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (5)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assemblyMitochondrial translation termination
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (5)
mitochondrial diseasemitochondrial complex IV deficiency, nuclear-typeMELAS syndromehereditary recurrent myoglobinuria
HGNC:7422UniProt:P00414
MTRFRMitochondrial translation release factor in rescueCandidate gene tested inTolerante
FUNÇÃO

Part of a mitoribosome-associated quality control pathway that prevents aberrant translation by responding to interruptions during elongation (PubMed:33243891). As heterodimer with MTRES1, ejects the unfinished nascent chain and peptidyl transfer RNA (tRNA), respectively, from stalled ribosomes. Recruitment of mitoribosome biogenesis factors to these quality control intermediates suggests additional roles for MTRES1 and MTRF during mitoribosome rescue (PubMed:33243891)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial ribosome-associated quality control
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 7

A mitochondrial disease resulting in encephalomyopathy. Clinical manifestations include psychomotor delay and regression, ataxia, optic atrophy, nystagmus and muscle atrophy and weakness.

OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 55combined oxidative phosphorylation defect type 7
HGNC:26784UniProt:Q9H3J6
IARS2Isoleucine--tRNA ligase, mitochondrialCandidate gene tested inRestrito
FUNÇÃO

Aminoacyl-tRNA synthetase that catalyzes the specific attachment of isoleucine to its cognate tRNA (tRNA(Ile))

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Mitochondrial protein degradationMitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia

An autosomal recessive disorder characterized by cataracts, short-stature secondary to growth hormone deficiency, sensorineural hearing deficit, peripheral sensory neuropathy, skeletal dysplasia, scoliosis, and facial dysmorphism.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
107.8 TPM
Linfócitos
84.2 TPM
Glândula adrenal
72.5 TPM
Artéria tibial
71.5 TPM
Tecido adiposo
69.7 TPM
OUTRAS DOENÇAS (2)
cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndromeLeigh syndrome
HGNC:29685UniProt:Q9NSE4
TRMT5tRNA (guanine(37)-N(1))-methyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Involved in mitochondrial tRNA methylation (PubMed:26189817). Specifically methylates the N1 position of guanosine-37 in various tRNAs. Methylation is not dependent on the nature of the nucleoside 5' of the target nucleoside. This is the first step in the biosynthesis of wybutosine (yW), a modified base adjacent to the anticodon of tRNAs and required for accurate decoding

LOCALIZAÇÃO

Mitochondrion matrixNucleusCytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of wybutosine at G37 of tRNA(Phe)
MECANISMO DE DOENÇA

Peripheral neuropathy with variable spasticity, exercise intolerance, and developmental delay

An autosomal recessive mitochondrial disorder with multisystemic and highly variable manifestations. Affected individuals suffer from a peripheral neuropathy, with distal muscle weakness and atrophy, and distal sensory impairment. Additional variable features include early-onset hypotonia and global developmental delay, poor or absent motor skills, exercise intolerance, poor growth, cerebellar signs, spasticity, and seizures. Biochemical analysis may show deficiencies in mitochondrial respiratory complex. Lactic acidosis is frequently observed.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
19.5 TPM
Fibroblastos
15.3 TPM
Linfócitos
11.9 TPM
Ovário
9.9 TPM
Nervo tibial
9.3 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation defect type 26
HGNC:23141UniProt:Q32P41
RRM2BRibonucleoside-diphosphate reductase subunit M2 BCandidate gene tested inTolerante
FUNÇÃO

Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical center required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (2)
TP53 Regulates Metabolic GenesInterconversion of nucleotide di- and triphosphates
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 8A

A disorder due to mitochondrial dysfunction characterized by various combinations of neonatal hypotonia, neurological deterioration, respiratory distress, lactic acidosis, and renal tubulopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.2 TPM
Tireoide
33.1 TPM
Fibroblastos
25.4 TPM
Aorta
22.0 TPM
Pulmão
20.7 TPM
OUTRAS DOENÇAS (7)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunctionmitochondrial DNA depletion syndrome 8aKearns-Sayre syndrome
HGNC:17296UniProt:Q7LG56
TXN2Thioredoxin, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Important for the control of mitochondrial reactive oxygen species homeostasis, apoptosis regulation and cell viability (PubMed:12032145, PubMed:12080052, PubMed:26626369) Is involved in various redox reactions including the reduction of protein disulfide bonds, through the reversible oxidation of its active center dithiol to a disulfide (By similarity)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Degradation of cysteine and homocysteineDetoxification of Reactive Oxygen Species
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 29

An autosomal recessive, infantile-onset, neurodegenerative disorder characterized by decreased activities of mitochondrial respiratory complexes I and III, severe cerebellar atrophy, epilepsy, dystonia, optic atrophy, and peripheral neuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
170.2 TPM
Linfócitos
135.1 TPM
Fibroblastos
102.0 TPM
Ovário
98.4 TPM
Tireoide
95.8 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation deficiency 29
HGNC:17772UniProt:Q99757
COQ4Ubiquinone biosynthesis protein COQ4 homolog, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Lyase that catalyzes the C1-decarboxylation of 4-hydroxy-3-methoxy-5-(all-trans-decaprenyl)benzoic acid into 2-methoxy-6-(all-trans-decaprenyl)phenol during ubiquinone biosynthesis

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Ubiquinol biosynthesis
MECANISMO DE DOENÇA

Coenzyme Q10 deficiency, primary, 7

An autosomal recessive disorder resulting from mitochondrial dysfunction and characterized by decreased levels of coenzyme Q10, and severe cardiac or neurologic symptoms soon after birth, usually resulting in death. Rarely, symptoms may have later onset.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
spastic ataxia 10, autosomal recessiveneonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome
HGNC:19693UniProt:Q9Y3A0
MARS2Methionine--tRNA ligase, mitochondrialCandidate gene tested inTolerante
LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Spastic ataxia 3, autosomal recessive

A neurologic disorder characterized by cerebellar ataxia, ataxic gait, spasticity, and hyperreflexia. Other variable features include dysarthria, dysmetria, mild cognitive impairment, urinary urgency and dystonic positioning.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
25.8 TPM
Esôfago - Mucosa
7.7 TPM
Baço
7.5 TPM
Fibroblastos
7.2 TPM
Glândula adrenal
7.2 TPM
OUTRAS DOENÇAS (2)
spastic ataxia 3combined oxidative phosphorylation defect type 25
HGNC:25133UniProt:Q96GW9
TRMT10CtRNA methyltransferase 10 homolog CCandidate gene tested inTolerante
FUNÇÃO

Mitochondrial tRNA N(1)-methyltransferase involved in mitochondrial tRNA maturation (PubMed:18984158, PubMed:21593607, PubMed:23042678, PubMed:27132592). Component of mitochondrial ribonuclease P, a complex composed of TRMT10C/MRPP1, HSD17B10/MRPP2 and PRORP/MRPP3, which cleaves tRNA molecules in their 5'-ends (PubMed:18984158). Together with HSD17B10/MRPP2, forms a subcomplex of the mitochondrial ribonuclease P, named MRPP1-MRPP2 subcomplex, which displays functions that are independent of the

LOCALIZAÇÃO

Mitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (3)
tRNA processing in the mitochondrionrRNA processing in the mitochondriontRNA modification in the mitochondrion
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 30

An autosomal recessive, severe mitochondrial disease characterized by lactic acidosis, hypotonia, feeding difficulties, deafness, and respiratory failure with fatal issue. Patient skeletal muscle cells show decreased activities of mitochondrial complexes I, III and IV.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
45.9 TPM
Fibroblastos
39.8 TPM
Fallopian Tube
23.3 TPM
Esôfago - Mucosa
21.3 TPM
Baço
20.9 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation defect type 30
HGNC:26022UniProt:Q7L0Y3
MIPEPMitochondrial intermediate peptidaseCandidate gene tested inTolerante
FUNÇÃO

Cleaves proteins, imported into the mitochondrion, to their mature size

LOCALIZAÇÃO

Mitochondrion matrix

MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 31

An autosomal recessive, severe mitochondrial disease with multisystemic manifestations appearing soon after birth or in early infancy. Clinical features include left ventricular non-compaction, global developmental delay, severe hypotonia, seizures, cataract, and abnormal movements. Death may occur in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
26.7 TPM
Skin Not Sun Exposed Suprapubic
26.3 TPM
Linfócitos
16.9 TPM
Fibroblastos
15.5 TPM
Coração - Átrio
15.4 TPM
OUTRAS DOENÇAS (1)
lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome
HGNC:7104UniProt:Q99797
MT-ATP8ATP synthase F(0) complex subunit 8Candidate gene tested inDesconhecido
FUNÇÃO

Subunit 8, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (PubMed:37244256). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside

LOCALIZAÇÃO

Mitochondrion membrane

VIAS BIOLÓGICAS (3)
Mitochondrial translation terminationFormation of ATP by chemiosmotic couplingCristae formation
MECANISMO DE DOENÇA

Mitochondrial complex V deficiency, mitochondrial 2

A mitochondrial disorder with heterogeneous clinical manifestations including neuropathy, ataxia, hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy can present with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct septal contours/morphologies with extremely varying clinical course.

OUTRAS DOENÇAS (4)
mitochondrial diseaseperiodic paralysis with later-onset distal motor neuropathymitochondrial proton-transporting ATP synthase complex deficiencyKearns-Sayre syndrome
HGNC:7415UniProt:P03928
NDUFB3NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3Candidate gene tested inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 25

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN25 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
145.0 TPM
Linfócitos
128.5 TPM
Coração - Átrio
121.7 TPM
Músculo esquelético
120.4 TPM
Rim - Medula
112.7 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 25mitochondrial complex I deficiency
HGNC:7698UniProt:O43676
NDUFV2NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (Probable). Parts of the peripheral arm of the enzyme, where the electrons from NADH are accepted by flavin mononucleotide (FMN) and then passed along a chain of iron-sulfur clusters by electron tunnelling to the final acceptor ubiquinone (Probable). Contains one iron-sulfur cluster (Probabl

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 7

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN7 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
143.4 TPM
Linfócitos
138.2 TPM
Coração - Ventrículo esquerdo
111.4 TPM
Fígado
99.1 TPM
Glândula adrenal
86.0 TPM
OUTRAS DOENÇAS (3)
mitochondrial complex I deficiency, nuclear type 7mitochondrial complex I deficiencyprogressive cavitating leukoencephalopathy
HGNC:7717UniProt:P19404
MT-ND1NADH-ubiquinone oxidoreductase chain 1Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:1959619). Essential for the catalytic activity and assembly of complex I (PubMed:1959619, PubMed:26929434)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Respiratory electron transportComplex I biogenesisMitochondrial translation terminationMitochondrial protein degradation
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (5)
mitochondrial diseaseMELAS syndromemitochondrial complex I deficiencymaternally-inherited Leigh syndrome
HGNC:7455UniProt:P03886
AIFM1Apoptosis-inducing factor 1, mitochondrialCandidate gene tested inAltamente restrito
FUNÇÃO

Functions both as NADH oxidoreductase and as regulator of apoptosis (PubMed:17094969, PubMed:20362274, PubMed:23217327, PubMed:33168626). In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into the cytosol and to the nucleus, where it functions as a proapoptotic factor in a caspase-independent pathway (PubMed:20362274). Release into the cytoplasm is mediated upon binding to poly-ADP-ribose chains (By similarity). The soluble form (AIFsol) found in the nuc

LOCALIZAÇÃO

Mitochondrion intermembrane spaceMitochondrion inner membraneCytoplasmNucleusCytoplasm, perinuclear regionMitochondrionCytoplasm, cytosol

MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 6

A mitochondrial disease resulting in a neurodegenerative disorder characterized by psychomotor delay, hypotonia, areflexia, muscle weakness and wasting. Some patients manifest prenatal ventriculomegaly and severe postnatal encephalomyopathy.

OUTRAS DOENÇAS (4)
X-linked hereditary sensory and autonomic neuropathy with hearing lossCharcot-Marie-Tooth disease X-linked recessive 4spondyloepimetaphyseal dysplasia, Bieganski typesevere X-linked mitochondrial encephalomyopathy
HGNC:8768UniProt:O95831
MT-ND2NADH-ubiquinone oxidoreductase chain 2Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:16996290). Essential for the catalytic activity and assembly of complex I (PubMed:16996290)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Respiratory electron transportComplex I biogenesisMitochondrial translation terminationMitochondrial protein degradation
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (4)
mitochondrial diseaseLeber hereditary optic neuropathymaternally-inherited Leigh syndromemitochondrial complex I deficiency
HGNC:7456UniProt:P03891
UQCC2Ubiquinol-cytochrome c reductase complex assembly factor 2Candidate gene tested inTolerante
FUNÇÃO

Required for the assembly of the ubiquinol-cytochrome c reductase complex (mitochondrial respiratory chain complex III or cytochrome b-c1 complex). Plays a role in the modulation of respiratory chain activities such as oxygen consumption and ATP production and via its modulation of the respiratory chain activity can regulate skeletal muscle differentiation and insulin secretion by pancreatic beta-cells. Involved in cytochrome b translation and/or stability

LOCALIZAÇÃO

Mitochondrion matrix, mitochondrion nucleoidMitochondrionMitochondrion intermembrane spaceMitochondrion matrixMitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex III assembly
MECANISMO DE DOENÇA

Mitochondrial complex III deficiency, nuclear type 7

A form of mitochondrial complex III deficiency, a disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. MC3DN7 is characterized by severe intrauterine growth retardation, neonatal lactic acidosis and renal tubular dysfunction. Additional clinical features include a dysmorphic facial appearance, delayed psychomotor development, autistic features, aggressive behavior, and mild sensorineural hearing loss.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
76.4 TPM
Coração - Átrio
54.8 TPM
Pituitária
54.1 TPM
Fibroblastos
53.5 TPM
Coração - Ventrículo esquerdo
48.2 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
mitochondrial complex III deficiency nuclear type 7mitochondrial complex III deficiency
HGNC:21237UniProt:Q9BRT2
UQCRC2Cytochrome b-c1 complex subunit 2, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex III assemblyMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex III deficiency, nuclear type 5

A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
245.0 TPM
Coração - Ventrículo esquerdo
227.3 TPM
Linfócitos
218.5 TPM
Coração - Átrio
189.2 TPM
Cólon transverso
159.7 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex III deficiency nuclear type 5mitochondrial complex III deficiency
HGNC:12586UniProt:P22695
MT-ATP6ATP synthase F(0) complex subunit aCandidate gene tested inDesconhecido
FUNÇÃO

Subunit a, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside the F(1

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationFormation of ATP by chemiosmotic couplingCristae formationMitochondrial protein degradation
MECANISMO DE DOENÇA

Neuropathy, ataxia, and retinitis pigmentosa

A syndrome characterized by variable combination of developmental delay, psychomotor retardation, hearing loss, optic atrophy and retinitis pigmentosa, dementia, seizures, ataxia, proximal neurogenic muscle weakness, and sensory neuropathy.

OUTRAS DOENÇAS (8)
mitochondrial diseasematernally-inherited Leigh syndromefamilial infantile bilateral striatal necrosismitochondrial proton-transporting ATP synthase complex deficiency
HGNC:7414UniProt:P00846
MT-TL1Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (7)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeMERRF syndrome
HGNC:7490
MT-ND4NADH-ubiquinone oxidoreductase chain 4Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:15250827, PubMed:8344246, PubMed:8644732). Essential for the catalytic activity and assembly of complex I (PubMed:15250827, PubMed:8344246, PubMed:8644732)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial translation termination
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (6)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeLeber plus disease
HGNC:7459UniProt:P03905
QRSL1Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Allows the formation of correctly charged Gln-tRNA(Gln) through the transamidation of misacylated Glu-tRNA(Gln) in the mitochondria. The reaction takes place in the presence of glutamine and ATP through an activated gamma-phospho-Glu-tRNA(Gln)

LOCALIZAÇÃO

Mitochondrion

MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 40

An autosomal recessive mitochondrial disorder characterized by prenatal or infantile onset, fetal hydrops, severe hypertrophic cardiomyopathy, poor growth, sensorineural hearing loss, hepatic dysfunction, lactic acidosis, and decreased activities of mitochondrial respiratory complexes I, III, IV, and V. The disorder is lethal, with death occurring in infancy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
17.2 TPM
Baço
12.2 TPM
Nervo tibial
10.9 TPM
Músculo esquelético
10.6 TPM
Fibroblastos
10.5 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation deficiency 40
HGNC:21020UniProt:Q9H0R6
MRPL3Large ribosomal subunit protein uL3mCandidate gene tested inTolerante
LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationMitochondrial ribosome-associated quality controlMitochondrial translation initiationMitochondrial translation elongation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 9

A mitochondrial disease characterized by failure to thrive, poor feeding, hypertrophic cardiomyopathy, hepatomegaly, and psychomotor retardation. Death in infancy has been observed in some cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
147.1 TPM
Fibroblastos
142.8 TPM
Testículo
72.3 TPM
Tireoide
70.7 TPM
Ovário
69.2 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation defect type 9
HGNC:10379UniProt:P09001
AARS2Alanine--tRNA ligase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:21549344). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine residues in target proteins, such as CGAS (PubMed:39322678). Acts as an inhibitor of cGAS/STING signaling by catalyzing lac

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 8

A mitochondrial disease characterized by a lethal infantile hypertrophic cardiomyopathy, generalized muscle dysfunction and some neurologic involvement. The liver is not affected.

OUTRAS DOENÇAS (4)
leukoencephalopathy, progressive, with ovarian failurecombined oxidative phosphorylation defect type 8leukoencephalopathy, diffuse hereditary, with spheroids 1obsolete ovarioleukodystrophy
HGNC:21022UniProt:Q5JTZ9
NDUFA9NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Required for proper complex I assembly (PubMed:28671271). Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 26

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN26 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
25.2 TPM
Coração - Ventrículo esquerdo
24.6 TPM
Músculo esquelético
24.5 TPM
Cérebro - Hemisfério cerebelar
21.7 TPM
Cerebelo
17.5 TPM
OUTRAS DOENÇAS (1)
mitochondrial complex I deficiency, nuclear type 26
HGNC:HGNC:7693UniProt:Q16795
NDUFA11NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 14

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN14 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
59.6 TPM
Coração - Átrio
58.8 TPM
Cólon sigmoide
58.4 TPM
Útero
57.8 TPM
Próstata
56.3 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 14mitochondrial complex I deficiency
HGNC:20371UniProt:Q86Y39
FBXL4F-box/LRR-repeat protein 4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Substrate-recognition component of the mitochondria-localized SCF-FBXL4 ubiquitin E3 ligase complex that plays a role in the restriction of mitophagy by controlling the degradation of BNIP3 and NIX mitophagy receptors (PubMed:36896912, PubMed:38992176). Rescues also mitochondrial injury through reverting hyperactivation of DRP1-mediated mitochondrial fission (By similarity)

LOCALIZAÇÃO

CytoplasmNucleusMitochondrion outer membrane

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 13

An autosomal recessive disorder characterized by early infantile onset of encephalopathy, hypotonia, lactic acidosis, and severe global developmental delay. Cells derived from patient tissues show defects in mitochondrial oxidative phosphorylation and decreased mtDNA content.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
15.8 TPM
Fibroblastos
11.0 TPM
Tireoide
10.4 TPM
Ovário
10.3 TPM
Cervix Endocervix
10.1 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
mitochondrial DNA depletion syndrome 13
HGNC:13601UniProt:Q9UKA2
FARS2Phenylalanine--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Is responsible for the charging of tRNA(Phe) with phenylalanine in mitochondrial translation. To a lesser extent, also catalyzes direct attachment of m-Tyr (an oxidized version of Phe) to tRNA(Phe), thereby opening the way for delivery of the misacylated tRNA to the ribosome and incorporation of ROS-damaged amino acid into proteins

LOCALIZAÇÃO

Mitochondrion matrixMitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 14

A severe multisystemic autosomal recessive disorder characterized by neonatal onset of global developmental delay, refractory seizures, and lactic acidosis. Biochemical studies show deficiencies of multiple mitochondrial respiratory enzymes.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
17.6 TPM
Testículo
15.4 TPM
Fibroblastos
13.6 TPM
Nervo tibial
12.8 TPM
Útero
12.7 TPM
OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 77combined oxidative phosphorylation defect type 14
HGNC:21062UniProt:O95363
HSD17B4Peroxisomal multifunctional enzyme type 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Bifunctional enzyme acting on the peroxisomal fatty acid beta-oxidation pathway. Catalyzes two of the four reactions in fatty acid degradation: hydration of 2-enoyl-CoA (trans-2-enoyl-CoA) to produce (3R)-3-hydroxyacyl-CoA, and dehydrogenation of (3R)-3-hydroxyacyl-CoA to produce 3-ketoacyl-CoA (3-oxoacyl-CoA), which is further metabolized by SCPx. Can use straight-chain and branched-chain fatty acids, as well as bile acid intermediates as substrates

LOCALIZAÇÃO

Peroxisome

VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

D-bifunctional protein deficiency

Disorder of peroxisomal fatty acid beta-oxidation.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
203.8 TPM
Glândula adrenal
129.8 TPM
Fígado
119.8 TPM
Pulmão
107.4 TPM
Brain Spinal cord cervical c-1
105.2 TPM
OUTRAS DOENÇAS (3)
Perrault syndrome 1d-bifunctional protein deficiencyPerrault syndrome 2
HGNC:5213UniProt:P51659
YARS2Tyrosine--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Myopathy with lactic acidosis and sideroblastic anemia 2

A rare oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. Affected individuals manifest sideroblastic anemia, progressive lethargy, muscle weakness, and exercise intolerance associated with persistent lactic acidemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
29.8 TPM
Linfócitos
29.0 TPM
Cervix Endocervix
16.4 TPM
Útero
16.2 TPM
Cervix Ectocervix
16.1 TPM
OUTRAS DOENÇAS (2)
myopathy, lactic acidosis, and sideroblastic anemia 2myopathy, lactic acidosis, and sideroblastic anemia
HGNC:24249UniProt:Q9Y2Z4
PUS1Pseudouridylate synthase 1 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Pseudouridylate synthase that catalyzes pseudouridylation of tRNAs and mRNAs (PubMed:15772074, PubMed:24722331). Acts on positions 27/28 in the anticodon stem and also positions 34 and 36 in the anticodon of an intron containing tRNA (PubMed:24722331). Also catalyzes pseudouridylation of mRNAs: mediates pseudouridylation of mRNAs with the consensus sequence 5'-UGUAG-3' (PubMed:31477916, PubMed:35051350). Acts as a regulator of pre-mRNA splicing by mediating pseudouridylation of pre-mRNAs at loca

LOCALIZAÇÃO

MitochondrionNucleusCytoplasm

VIAS BIOLÓGICAS (1)
tRNA modification in the nucleus and cytosol
MECANISMO DE DOENÇA

Myopathy with lactic acidosis and sideroblastic anemia 1

A rare oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. Affected individuals manifest progressive muscle weakness, exercise intolerance, lactic acidosis, sideroblastic anemia and delayed growth.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
19.0 TPM
Fibroblastos
15.3 TPM
Baço
13.7 TPM
Testículo
13.4 TPM
Fallopian Tube
10.6 TPM
OUTRAS DOENÇAS (2)
myopathy, lactic acidosis, and sideroblastic anemia 1myopathy, lactic acidosis, and sideroblastic anemia
HGNC:15508UniProt:Q9Y606
ATP5F1EATP synthase F(1) complex subunit epsilon, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Subunit epsilon, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (PubMed:37244256). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating i

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Formation of ATP by chemiosmotic couplingCristae formation
MECANISMO DE DOENÇA

Mitochondrial complex V deficiency, nuclear type 3

A mitochondrial disorder with heterogeneous clinical manifestations including dysmorphic features, psychomotor retardation, hypotonia, growth retardation, cardiomyopathy, enlarged liver, hypoplastic kidneys and elevated lactate levels in urine, plasma and cerebrospinal fluid.

OUTRAS DOENÇAS (2)
mitochondrial complex V (ATP synthase) deficiency, nuclear type 3mitochondrial proton-transporting ATP synthase complex deficiency
HGNC:838UniProt:P56381
COX11Cytochrome c oxidase assembly protein COX11, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Assembly factor for cytochrome c oxidase (respiratory chain complex IV, CIV) (PubMed:35750769). Probably acts as a metallochaperone that delivers copper to the copper B site of COX1 (PubMed:35750769)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 23

A primary mitochondrial disease, a clinically heterogeneous group of disorders arising from dysfunction of the mitochondrial respiratory chain. MC4DN23 is an autosomal recessive form characterized by infantile-onset encephalopathy. Clinical features include brain atrophy, severe developmental delay, seizures, and dyskinetic movement abnormalities.

VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
mitochondrial complex IV deficiency, nuclear type 23
HGNC:HGNC:2261UniProt:Q9Y6N1
COX5ACytochrome c oxidase subunit 5A, mitochondrialDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (5)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assemblyMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 20

An autosomal recessive mitochondrial disorder with onset in early infancy. MC4DN20 is characterized by pulmonary arterial hypertension, poor feeding, failure to thrive, hypotonia, delayed development, increased serum lactate and metabolic acidosis. Death in infancy occurs due to cardiorespiratory failure. Patient tissues show variably decreased levels and activity of mitochondrial respiratory complex IV.

OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 20mitochondrial complex IV deficiency, nuclear-type
HGNC:2267UniProt:P20674
NDUFV1NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:28844695). Part of the peripheral arm of the enzyme, where the electrons from NADH are accepted by flavin mononucleotide (FMN) and then passed along a chain of iron-sulfur clusters by electron tunnelling to the final acceptor ubiquinone (PubMed:28844695). Contains FMN, which is the i

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 4

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN4 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
240.6 TPM
Coração - Ventrículo esquerdo
236.3 TPM
Linfócitos
234.0 TPM
Cerebelo
233.0 TPM
Músculo esquelético
222.6 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 4mitochondrial complex I deficiency
HGNC:7716UniProt:P49821
DGUOKDeoxyguanosine kinase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Phosphorylates deoxyguanosine and deoxyadenosine in the mitochondrial matrix, with the highest efficiency for deoxyguanosine (PubMed:11687801, PubMed:17073823, PubMed:23043144, PubMed:8692979, PubMed:8706825). In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on DGUOK and TK2. Phosphorylates certain nucleoside analogs (By similarity). Widely used as target of antiviral and chemotherapeutic agents

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 3

A disorder due to mitochondrial dysfunction characterized by onset in infancy of progressive liver failure, hypoglycemia, increased lactate in body fluids, and neurologic abnormalities including hypotonia, encephalopathy, peripheral neuropathy. Affected tissues show both decreased activity of the mtDNA-encoded respiratory chain complexes and mtDNA depletion.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
78.1 TPM
Pituitária
72.5 TPM
Ovário
63.9 TPM
Aorta
61.4 TPM
Testículo
61.4 TPM
OUTRAS DOENÇAS (3)
mitochondrial DNA depletion syndrome 3 (hepatocerebral type)portal hypertension, noncirrhotic, 1progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4
HGNC:2858UniProt:Q16854
GUK1Guanylate kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the phosphorylation of GMP to GDP. Essential enzyme for recycling GMP and indirectly, cyclic GMP (cGMP) (PubMed:31201273). Involved in the cGMP metabolism in photoreceptors (By similarity). It may also have a role in the survival and growth progression of some tumors (PubMed:31201273). In addition to its physiological role, GUK1 is essential for converting prodrugs used for the treatment of cancers and viral infections into their pharmacologically active metabolites, most notably acycl

LOCALIZAÇÃO

Photoreceptor inner segmentCytoplasm, cytosolMitochondrion

VIAS BIOLÓGICAS (2)
Interconversion of nucleotide di- and triphosphatesAzathioprine ADME
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 21

An autosomal recessive mitochondrial disorder characterized by ptosis, ophthalmoparesis, myopathic proximal limb weakness, variable hepatopathy, and altered T-lymphocyte profiles. Multiple mtDNA deletions and depletion are detected in muscle, as well as mitochondrial respiratory chain deficiencies.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
190.6 TPM
Aorta
151.5 TPM
Nervo tibial
150.8 TPM
Skin Not Sun Exposed Suprapubic
143.3 TPM
Brain Frontal Cortex BA9
140.6 TPM
OUTRAS DOENÇAS (1)
mitochondrial dna depletion syndrome 21
HGNC:HGNC:4693UniProt:Q16774
TYMPThymidine phosphorylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Pyrimidine salvagePyrimidine catabolism
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 1, MNGIE type

A multisystem disease associated with mitochondrial dysfunction. It is clinically characterized by onset between the second and fifth decades of life, ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility (often pseudoobstruction), diffuse leukoencephalopathy, cachexia, peripheral neuropathy, and myopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
330.6 TPM
Pulmão
260.6 TPM
Baço
215.3 TPM
Tecido adiposo
140.0 TPM
Adipose Visceral Omentum
116.4 TPM
OUTRAS DOENÇAS (2)
mitochondrial DNA depletion syndrome 1mitochondrial neurogastrointestinal encephalomyopathy
HGNC:3148UniProt:P19971
ATP5F1AATP synthase F(1) complex subunit alpha, mitochondrialDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Subunit alpha, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside the

LOCALIZAÇÃO

MitochondrionMitochondrion inner membraneCell membrane

VIAS BIOLÓGICAS (3)
Formation of ATP by chemiosmotic couplingCristae formationMitochondrial protein degradation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 22

A mitochondrial disorder characterized by intrauterine growth retardation, microcephaly, hypotonia, pulmonary hypertension, failure to thrive, encephalopathy, and heart failure.

OUTRAS DOENÇAS (4)
mitochondrial complex V (ATP synthase) deficiency, nuclear type 4Amitochondrial complex V (ATP synthase) deficiency, nuclear type 4Bcombined oxidative phosphorylation deficiency 22mitochondrial proton-transporting ATP synthase complex deficiency
HGNC:823UniProt:P25705
TMEM70Transmembrane protein 70, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Scaffold protein that participates in the c-ring assembly of mitochondrial ATP synthase (F(1)F(0) ATP synthase or complex V) by facilitating the membrane insertion and oligomer formation of the subunit c/ATP5MC1 through its interaction (PubMed:31652072, PubMed:32275929, PubMed:33359711, PubMed:33753518). Therefore, participates in the early stage of mitochondrial ATP synthase biogenesis and also protects subunit c/ATP5MC1 against intramitochondrial proteolysis (PubMed:18953340, PubMed:20937241,

LOCALIZAÇÃO

Mitochondrion inner membrane

MECANISMO DE DOENÇA

Mitochondrial complex V deficiency, nuclear type 2

A mitochondrial disorder with heterogeneous clinical manifestations including dysmorphic features, psychomotor retardation, hypotonia, growth retardation, cardiomyopathy, enlarged liver, hypoplastic kidneys and elevated lactate levels in urine, plasma and cerebrospinal fluid.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
54.5 TPM
Linfócitos
32.1 TPM
Glândula adrenal
29.1 TPM
Brain Frontal Cortex BA9
28.8 TPM
Adipose Visceral Omentum
26.8 TPM
OUTRAS DOENÇAS (1)
mitochondrial complex V (ATP synthase) deficiency, nuclear type 2
HGNC:26050UniProt:Q9BUB7
LRPPRCLeucine-rich PPR motif-containing protein, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a role in RNA metabolism in both nuclei and mitochondria. In the nucleus binds to HNRPA1-associated poly(A) mRNAs and is part of nmRNP complexes at late stages of mRNA maturation which are possibly associated with nuclear mRNA export. Positively modulates nuclear export of mRNAs containing the EIF4E sensitivity element (4ESE) by binding simultaneously to both EIF4E and the 4ESE and acting as a platform for assembly for the RNA export complex (PubMed:19262567, PubMed:28325843). Also bind

LOCALIZAÇÃO

MitochondrionNucleusNucleus, nucleoplasmNucleus inner membraneNucleus outer membrane

VIAS BIOLÓGICAS (2)
Mitochondrial mRNA modificationMitochondrial RNA degradation
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 5

An autosomal recessive, severe mitochondrial disease with multisystemic manifestations and early onset. Clinical features include delayed psychomotor development, impaired intellectual development with speech delay, mild dysmorphic facial features, hypotonia, ataxia, and seizures. Brain imaging shows bilaterally symmetrical necrotic lesions in subcortical brain regions. Mortality is high, due to episodes of severe metabolic acidosis and coma.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
113.8 TPM
Cérebro - Hemisfério cerebelar
71.9 TPM
Fibroblastos
69.4 TPM
Músculo esquelético
59.7 TPM
Cerebelo
56.5 TPM
OUTRAS DOENÇAS (1)
congenital lactic acidosis, Saguenay-Lac-Saint-Jean type
HGNC:15714UniProt:P42704
COX20Cytochrome c oxidase assembly protein COX20, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Essential for the assembly of the mitochondrial respiratory chain complex IV (CIV), also known as cytochrome c oxidase (PubMed:23125284). Acts as a chaperone in the early steps of cytochrome c oxidase subunit II (MT-CO2/COX2) maturation, stabilizing the newly synthesized protein and presenting it to metallochaperones SCO1/2 which in turn facilitates the incorporation of the mature MT-CO2/COX2 into the assembling CIV holoenzyme (PubMed:24403053)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 11

An autosomal recessive mitochondrial disorder with onset in childhood or adolescence. MC4DN11 is characterized by walking difficulties, cerebellar ataxia, dystonia, choreoathetotic movements and dysarthria. Additional features may include sensory axonal neuropathy, cerebellar atrophy, and mild speech delay. Cognitive function is normal. Serum lactate levels are increased. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 11mitochondrial complex IV deficiency, nuclear-type
HGNC:26970UniProt:Q5RI15
NDUFS3NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:14729820, PubMed:30140060). Essential for the catalytic activity and assembly of complex I (PubMed:14729820, PubMed:24028823, PubMed:30140060)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 8

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN8 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
78.6 TPM
Cérebro - Hemisfério cerebelar
77.7 TPM
Brain Caudate basal ganglia
72.3 TPM
Brain Putamen basal ganglia
68.8 TPM
Brain Frontal Cortex BA9
68.7 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 8mitochondrial complex I deficiency
HGNC:7710UniProt:O75489
TMEM126BComplex I assembly factor TMEM126B, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

As part of the MCIA complex, involved in the assembly of the mitochondrial complex I (PubMed:27374773, PubMed:27374774, PubMed:32320651). Participates in constructing the membrane arm of complex I (PubMed:24191001)

LOCALIZAÇÃO

Mitochondrion membrane

VIAS BIOLÓGICAS (1)
Complex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 29

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN29 transmission pattern is consistent with autosomal recessive inheritance.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
44.8 TPM
Útero
40.8 TPM
Nervo tibial
40.0 TPM
Cervix Endocervix
38.4 TPM
Fibroblastos
38.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 29mitochondrial complex I deficiency
HGNC:30883UniProt:Q8IUX1
MTFMTMethionyl-tRNA formyltransferase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Methionyl-tRNA formyltransferase that formylates methionyl-tRNA in mitochondria and is crucial for translation initiation

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial translation initiation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 15

An autosomal recessive, mitochondrial, neurologic disorder characterized by features of Leigh syndrome and combined oxidative phosphorylation deficiency. Clinical features include mild global developmental delay, white matter abnormalities, ataxia, incoordination, speech and reading difficulties, T2-weighted hyperintensities in the basal ganglia, corpus callosum, and brainstem.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
12.8 TPM
Fallopian Tube
12.8 TPM
Cervix Endocervix
12.1 TPM
Cervix Ectocervix
11.7 TPM
Cérebro - Hemisfério cerebelar
11.6 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 27combined oxidative phosphorylation defect type 15
HGNC:29666UniProt:Q96DP5
NDUFA1NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1Disease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 12

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
754.6 TPM
Coração - Átrio
614.2 TPM
Rim - Medula
479.1 TPM
Músculo esquelético
469.9 TPM
Linfócitos
453.6 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 12mitochondrial complex I deficiency
HGNC:7683UniProt:O15239
TRMUMitochondrial tRNA-specific 2-thiouridylase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the 2-thiolation of uridine at the wobble position (U34) of mitochondrial tRNA(Lys), tRNA(Glu) and tRNA(Gln). Required for the formation of 5-taurinomethyl-2-thiouridine (tm5s2U) of mitochondrial tRNA(Lys), tRNA(Glu), and tRNA(Gln) at the wobble position. ATP is required to activate the C2 atom of the wobble base

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
tRNA modification in the mitochondrion
MECANISMO DE DOENÇA

Deafness, aminoglycoside-induced

A form of sensorineural deafness characterized by moderate-to-profound hearing loss and mitochondrial inheritance. It is induced by exposure to aminoglycosides.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
22.9 TPM
Cérebro - Hemisfério cerebelar
21.9 TPM
Linfócitos
20.7 TPM
Cervix Endocervix
19.9 TPM
Pituitária
19.9 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (4)
acute infantile liver failure due to synthesis defect of mtDNA-encoded proteinsmitochondrial myopathy with reversible cytochrome C oxidase deficiencymitochondrial non-syndromic sensorineural hearing lossdeafness, aminoglycoside-induced
HGNC:25481UniProt:O75648
LARS2Leucine--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of leucine to its cognate tRNA

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Perrault syndrome 4

An autosomal recessive, sex-influenced disorder characterized by sensorineural deafness in both males and females, and ovarian dysgenesis in females. Affected females have primary amenorrhea, streak gonads, and infertility, whereas affected males show normal pubertal development and are fertile.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
22.1 TPM
Fibroblastos
20.3 TPM
Córtex cerebral
13.1 TPM
Brain Frontal Cortex BA9
13.1 TPM
Brain Nucleus accumbens basal ganglia
12.9 TPM
OUTRAS DOENÇAS (4)
Perrault syndrome 4hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndromePerrault syndrome 2Perrault syndrome 1
HGNC:17095UniProt:Q15031
HARS2D-aminoacyl-tRNA deacylase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Possible ATPase (PubMed:15653697) involved in DNA replication, may facilitate loading of CDC45 onto pre-replication complexes (PubMed:20065034) An aminoacyl-tRNA editing enzyme that deacylates mischarged D-aminoacyl-tRNAs. Also deacylates mischarged glycyl-tRNA(Ala), protecting cells against glycine mischarging by AlaRS. Acts via tRNA-based rather than protein-based catalysis; rejects L-amino acids rather than detecting D-amino acids in the active site. By recycling D-aminoacyl-tRNA to D-amino a

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
60.5 TPM
Cerebelo
58.0 TPM
Útero
55.0 TPM
Nervo tibial
52.6 TPM
Fallopian Tube
49.9 TPM
OUTRAS DOENÇAS (2)
Perrault syndrome 2Perrault syndrome 1
HGNC:4817UniProt:Q8TEA8
POLGDNA polymerase subunit gamma-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Replicates both heavy and light strands of the circular mtDNA genome using a single-stranded DNA template, RNA primers and the four deoxyribonucleoside triphosphates as substrates (PubMed:11477093, PubMed:11897778, PubMed:15917273, PubMed:19837034, PubMed:9558343). Has 5' -> 3' polymerase activity. Functionally interacts with TWNK and SSBP1 at the replication fork to form a highly processiv

LOCALIZAÇÃO

MitochondrionMitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (1)
Strand-asynchronous mitochondrial DNA replication
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
48.3 TPM
Linfócitos
42.0 TPM
Baço
41.5 TPM
Útero
40.9 TPM
Pulmão
38.7 TPM
OUTRAS DOENÇAS (11)
sensory ataxic neuropathy, dysarthria, and ophthalmoparesismitochondrial DNA depletion syndrome 4bmitochondrial DNA depletion syndrome 4amitochondrial disease
HGNC:9179UniProt:P54098
ATP5F1DATP synthase F(1) complex subunit delta, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Subunit delta, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable) (PubMed:37244256). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk r

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Formation of ATP by chemiosmotic couplingCristae formation
MECANISMO DE DOENÇA

Mitochondrial complex V deficiency, nuclear type 5

A mitochondrial disorder characterized by childhood onset of episodic metabolic decompensation featuring lactic acidosis and hyperammonemia accompanied by ketoacidosis or hypoglycemia. Chronic manifestations include developmental delay, easy fatiguability, and 3-methylglutaconic aciduria. The transmission pattern of MC5DN5 is consistent with autosomal recessive inheritance.

OUTRAS DOENÇAS (2)
mitochondrial complex V (ATP synthase) deficiency, nuclear type 5mitochondrial proton-transporting ATP synthase complex deficiency
HGNC:837UniProt:P30049
SCO2Cytochrome c oxidase assembly factor SCO2Disease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Copper metallochaperone essential for the synthesis and maturation of cytochrome c oxidase subunit II (MT-CO2/COX2); together with SCO1, facilitates the incorporation of copper into the Cu(A) site of MT-CO2/COX2 (PubMed:15229189, PubMed:17189203, PubMed:19336478, PubMed:35750769). Could also act as a thiol-disulfide oxidoreductase to regulate the redox state of the cysteines in SCO1 during maturation of MT-CO2/COX2 (PubMed:19336478)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
TP53 Regulates Metabolic GenesComplex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 2

An autosomal recessive, severe mitochondrial disorder characterized by hypotonia, global developmental delay, hypertrophic cardiomyopathy, lactic acidosis, gliosis, and neuronal loss in basal ganglia, brainstem and spinal cord. Serum lactate is increased, and laboratory studies show decreased mitochondrial complex IV protein and activity levels in various tissues, including heart and skeletal muscle. Most patients die in infancy of cardiorespiratory failure.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
32.4 TPM
Pulmão
32.3 TPM
Fibroblastos
29.5 TPM
Esôfago - Mucosa
28.2 TPM
Fallopian Tube
28.1 TPM
OUTRAS DOENÇAS (5)
cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1myopia 6autosomal recessive axonal charcot-marie-tooth disease due to copper metabolism defectfatal infantile encephalocardiomyopathy
HGNC:10604UniProt:O43819
COA6Cytochrome c oxidase assembly factor 6 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the maturation of the mitochondrial respiratory chain complex IV subunit MT-CO2/COX2. Thereby, may regulate early steps of complex IV assembly. Mitochondrial respiratory chain complex IV or cytochrome c oxidase is the component of the respiratory chain that catalyzes the transfer of electrons from intermembrane space cytochrome c to molecular oxygen in the matrix and as a consequence contributes to the proton gradient involved in mitochondrial ATP synthesis. May also be required for

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 13

An autosomal recessive, infantile disorder with a fatal course in the first weeks of life, characterized by hypertrophic cardiomyopathy, left ventricular non-compaction, lactic acidosis, metabolic hypotonia, and mitochondrial complex IV deficiency.

OUTRAS DOENÇAS (2)
cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4fatal infantile encephalocardiomyopathy
HGNC:18025UniProt:Q5JTJ3
UQCRQCytochrome b-c1 complex subunit 8Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex III assemblyMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex III deficiency, nuclear type 4

A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
368.3 TPM
Músculo esquelético
306.8 TPM
Fígado
286.8 TPM
Coração - Átrio
284.2 TPM
Fibroblastos
237.5 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex III deficiency nuclear type 4mitochondrial complex III deficiency
HGNC:29594UniProt:O14949
UQCRFS1Cytochrome b-c1 complex subunit Rieske, mitochondrialDisease-causing germline mutation(s) inModerado
FUNÇÃO

Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation (PubMed:31883641). The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succi

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex III assembly
MECANISMO DE DOENÇA

Mitochondrial complex III deficiency, nuclear type 10

A form of mitochondrial complex III deficiency, a disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. MC3DN10 is an autosomal recessive form characterized by fetal bradycardia, poor feeding, hypotonia, hypertrophic cardiomyopathy, alopecia totalis, low mitochondrial complex III activity and lactic acidosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
133.8 TPM
Coração - Ventrículo esquerdo
102.0 TPM
Coração - Átrio
86.6 TPM
Rim - Medula
78.3 TPM
Linfócitos
76.4 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex III deficiency, nuclear type 10mitochondrial complex III deficiency
HGNC:12587UniProt:P47985
NDUFS7NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:17275378). Essential for the catalytic activity of complex I (PubMed:17275378)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 3

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN3 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
88.0 TPM
Cérebro - Hemisfério cerebelar
84.6 TPM
Cerebelo
84.0 TPM
Testículo
68.2 TPM
Coração - Ventrículo esquerdo
64.3 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 3mitochondrial complex I deficiency
HGNC:7714UniProt:O75251
NDUFA10NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 22

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN22 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
95.5 TPM
Cerebelo
92.4 TPM
Nervo tibial
52.4 TPM
Coração - Ventrículo esquerdo
50.1 TPM
Linfócitos
47.7 TPM
OUTRAS DOENÇAS (1)
mitochondrial complex I deficiency, nuclear type 22
HGNC:HGNC:7684UniProt:O95299
NUBPLIron-sulfur cluster transfer protein NUBPLDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Iron-sulfur cluster transfer protein involved in the assembly of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) (PubMed:19752196). May deliver one or more Fe-S clusters to complex I subunits (PubMed:19752196)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Complex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 21

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN21 transmission pattern is consistent with autosomal recessive inheritance.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
10.0 TPM
Ovário
7.6 TPM
Nervo tibial
7.4 TPM
Linfócitos
7.3 TPM
Tecido adiposo
7.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 21mitochondrial complex I deficiency
HGNC:20278UniProt:Q8TB37
NDUFS8NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:22499348). Essential for the catalytic activity and assembly of complex I (PubMed:22499348)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 2

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN2 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
151.7 TPM
Coração - Ventrículo esquerdo
104.0 TPM
Coração - Átrio
101.5 TPM
Músculo esquelético
94.8 TPM
Pituitária
93.8 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 2mitochondrial complex I deficiency
HGNC:7715UniProt:O00217
TWNKTwinkle mtDNA helicaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial helicase involved in mtDNA replication and repair (PubMed:12975372, PubMed:15167897, PubMed:17324440, PubMed:18039713, PubMed:18971204, PubMed:25824949, PubMed:26887820, PubMed:27226550). Might have a role in mtDNA repair (PubMed:27226550). Has DNA strand separation activity needed to form a processive replication fork for leading strand synthesis which is catalyzed by the formation of a replisome complex with POLG and mtSDB (PubMed:12975372, PubMed:15167897, PubMed:18039713, PubMe

LOCALIZAÇÃO

Mitochondrion matrix, mitochondrion nucleoidMitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Strand-asynchronous mitochondrial DNA replicationMitochondrial protein degradationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 3

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
21.9 TPM
Testículo
20.3 TPM
Fibroblastos
14.6 TPM
Ovário
10.6 TPM
Útero
10.3 TPM
OUTRAS DOENÇAS (8)
mitochondrial DNA depletion syndrome 7 (hepatocerebral type)Perrault syndrome 5progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3autosomal dominant progressive external ophthalmoplegia
HGNC:1160UniProt:Q96RR1
SUCLA2Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

ATP-specific succinyl-CoA synthetase functions in the citric acid cycle (TCA), coupling the hydrolysis of succinyl-CoA to the synthesis of ATP and thus represents the only step of substrate-level phosphorylation in the TCA (PubMed:15877282, PubMed:34492704, PubMed:40108300). The beta subunit provides nucleotide specificity of the enzyme and binds the substrate succinate, while the binding sites for coenzyme A and phosphate are found in the alpha subunit (By similarity). Also able to act as an AT

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Citric acid cycle (TCA cycle)
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 5

A disorder due to mitochondrial dysfunction. It is characterized by infantile onset of hypotonia, neurologic deterioration, a hyperkinetic-dystonic movement disorder, external ophthalmoplegia, deafness, variable renal tubular dysfunction, and mild methylmalonic aciduria in some patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
60.1 TPM
Cérebro - Hemisfério cerebelar
57.5 TPM
Brain Frontal Cortex BA9
44.4 TPM
Cerebelo
44.3 TPM
Artéria tibial
37.9 TPM
OUTRAS DOENÇAS (1)
mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria
HGNC:11448UniProt:Q9P2R7
RARS2Probable arginine--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of arginine to tRNA(Arg) in a two-step reaction: arginine is first activated by ATP to form Arg-AMP and then transferred to the acceptor end of tRNA(Arg)

LOCALIZAÇÃO

Mitochondrion membrane

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 6

A disorder characterized by an abnormally small cerebellum and brainstem, infantile encephalopathy, generalized hypotonia, lethargy and poor feeding. Recurrent apnea, intractable seizures occur early in the course of this condition.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
47.3 TPM
Glândula adrenal
46.1 TPM
Útero
43.0 TPM
Cervix Ectocervix
42.3 TPM
Cervix Endocervix
42.1 TPM
OUTRAS DOENÇAS (1)
pontocerebellar hypoplasia type 6
HGNC:21406UniProt:Q5T160
ERAL1GTPase Era, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable GTPase that plays a role in the mitochondrial ribosomal small subunit assembly. Specifically binds the 12S mitochondrial rRNA (12S mt-rRNA) to a 33 nucleotide section delineating the 3' terminal stem-loop region. May act as a chaperone that protects the 12S mt-rRNA on the 28S mitoribosomal subunit during ribosomal small subunit assembly

LOCALIZAÇÃO

Mitochondrion matrixMitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationMitochondrial ribosome-associated quality controlMitochondrial translation initiationMitochondrial translation elongation
MECANISMO DE DOENÇA

Perrault syndrome 6

A form of Perrault syndrome, a sex-influenced disorder characterized by sensorineural deafness in both males and females, and ovarian dysgenesis in females. Affected females have primary amenorrhea, streak gonads, and infertility, whereas affected males show normal pubertal development and are fertile. PRLTS6 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
88.6 TPM
Cerebelo
84.5 TPM
Linfócitos
71.5 TPM
Fibroblastos
68.2 TPM
Útero
63.8 TPM
OUTRAS DOENÇAS (3)
Perrault syndrome 6Perrault syndrome 1Perrault syndrome 2
HGNC:3424UniProt:O75616
AFG3L2Mitochondrial inner membrane m-AAA protease component AFG3L2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic component of the m-AAA protease, a protease that plays a key role in proteostasis of inner mitochondrial membrane proteins, and which is essential for axonal and neuron development (PubMed:19748354, PubMed:28396416, PubMed:29932645, PubMed:30683687, PubMed:31327635, PubMed:37917749, PubMed:38157846). AFG3L2 possesses both ATPase and protease activities: the ATPase activity is required to unfold substrates, threading them into the internal proteolytic cavity for hydrolysis into small pe

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Processing of SMDT1Mitochondrial protein degradation
MECANISMO DE DOENÇA

Spinocerebellar ataxia 28

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA28 is an autosomal dominant cerebellar ataxia (ADCA) with a slow progressive course and no evidence of sensory involvement or cognitive impairment.

OUTRAS DOENÇAS (3)
optic atrophy 12spinocerebellar ataxia type 28spastic ataxia 5
HGNC:315UniProt:Q9Y4W6
COX6B1Cytochrome c oxidase subunit 6B1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 7

An autosomal recessive mitochondrial disorder characterized by encephalomyopathy resulting in variable clinical manifestations. Features include muscle weakness, gait disturbances, neurodegeneration, cognitive decline, metabolic acidosis, feeding difficulties, poor overall growth, cortical visual impairment, and hypertrophic cardiomyopathy. Serum lactate levels are increased. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV.

OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 7mitochondrial complex IV deficiency, nuclear-type
HGNC:2280UniProt:P14854
COX10Protoheme IX farnesyltransferase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts protoheme IX and farnesyl diphosphate to heme O

LOCALIZAÇÃO

Mitochondrion membrane

VIAS BIOLÓGICAS (1)
Heme biosynthesis
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 3

An autosomal recessive mitochondrial disorder characterized by cytochrome c oxidase deficiency. Clinical features include muscle weakness, hypotonia, ataxia, ptosis, metabolic acidosis, poor feeding, delayed motor development, anemia, sensorineural hearing loss, and cardiomyopathy.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 3mitochondrial complex IV deficiency, nuclear-type
HGNC:2260UniProt:Q12887
SURF1Surfeit locus protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the MITRAC (mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex) complex, that regulates cytochrome c oxidase assembly

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 1

An autosomal recessive disorder of the mitochondrial respiratory chain characterized by early-onset, rapidly progressive encephalopathy, neurodegeneration, and loss of motor and cognitive skills. Affected individuals show hypotonia, failure to thrive, loss of the ability to sit or walk, poor communication, poor eye contact, oculomotor abnormalities, as well as deafness, ataxia, tremor, and brisk tendon reflexes. Brain imaging shows bilateral symmetric lesions in the basal ganglia. Lactate levels in serum and cerebrospinal fluid are increased. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV. Death in childhood may occur, often due to central respiratory failure.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
67.2 TPM
Artéria tibial
65.0 TPM
Aorta
63.9 TPM
Cólon sigmoide
62.4 TPM
Esôfago - Junção
60.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 1Charcot-Marie-Tooth disease type 4K
HGNC:11474UniProt:Q15526
NDUFS2NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:22036843, PubMed:28031252, PubMed:30922174). Essential for the catalytic activity of complex I (PubMed:22036843, PubMed:30922174). Essential for the assembly of complex I (By similarity). Redox-sensitive, critical component of the oxygen-sensing pathway in the pulmonary vasculature w

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 6

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN6 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
154.5 TPM
Ovário
130.0 TPM
Cérebro - Hemisfério cerebelar
124.7 TPM
Coração - Ventrículo esquerdo
120.8 TPM
Cerebelo
120.6 TPM
OUTRAS DOENÇAS (4)
mitochondrial complex I deficiency, nuclear type 6Leber-like hereditary optic neuropathy, autosomal recessive 2mitochondrial complex I deficiencyLeber hereditary optic neuropathy
HGNC:7708UniProt:O75306
NDUFA8NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis (PubMed:27626371, PubMed:32385911, PubMed:33153867). Complex I functions in the transfer of electrons from NADH to the respiratory chain (PubMed:27626371). The immediate electron acceptor for the enzyme is believed to be ubiquinone (PubMed:27626371)

LOCALIZAÇÃO

Mitochondrion inner membraneMitochondrion intermembrane spaceMitochondrion

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 37

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN37 features include developmental delay, cerebral atrophy, epilepsy, growth retardation, congenital myopathy with disproportion of fibers, and severely decreased activity of complex I. MC1DN37 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
220.3 TPM
Coração - Átrio
208.0 TPM
Testículo
204.3 TPM
Brain Frontal Cortex BA9
172.0 TPM
Cólon sigmoide
162.4 TPM
OUTRAS DOENÇAS (1)
mitochondrial complex I deficiency, nuclear type 37
HGNC:HGNC:7692UniProt:P51970
NDUFAF6NADH dehydrogenase (ubiquinone) complex I, assembly factor 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the assembly of mitochondrial NADH:ubiquinone oxidoreductase complex (complex I) at early stages. May play a role in the biogenesis of complex I subunit MT-ND1

LOCALIZAÇÃO

Mitochondrion inner membraneCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Complex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 17

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN17 transmission pattern is consistent with autosomal recessive inheritance.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
7.9 TPM
Tireoide
7.7 TPM
Testículo
7.2 TPM
Nervo tibial
7.0 TPM
Cerebelo
6.5 TPM
OUTRAS DOENÇAS (3)
mitochondrial complex I deficiency, nuclear type 17Fanconi renotubular syndrome 5primary Fanconi syndrome
HGNC:28625UniProt:Q330K2
MRM2rRNA methyltransferase 2, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

S-adenosyl-L-methionine-dependent 2'-O-ribose methyltransferase that catalyzes the formation of 2'-O-methyluridine at position 1369 (Um1369) in the 16S mitochondrial large subunit ribosomal RNA (mtLSU rRNA), a universally conserved modification in the peptidyl transferase domain of the mtLSU rRNA (PubMed:25009282, PubMed:25074936, PubMed:35177605). This activity may require prior 2'-O-methylguanosine modification at position 1370 (Gm1370) by MRM3 (PubMed:35177605). Essential for late-stage assem

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
rRNA modification in the mitochondrion
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 17

An autosomal recessive mitochondrial disorder characterized by childhood onset of rapidly progressive encephalopathy, stroke-like episodes, lactic acidosis, hypocitrullinemia, multiple defects of oxidative phosphorylation, mitochondrial complex I and IV deficiency, and reduced mtDNA copy number.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
49.9 TPM
Fibroblastos
31.2 TPM
Baço
22.1 TPM
Útero
20.5 TPM
Testículo
20.4 TPM
OUTRAS DOENÇAS (1)
mitochondrial DNA depletion syndrome 17
HGNC:HGNC:16352UniProt:Q9UI43

Variantes genéticas (ClinVar)

199 variantes patogênicas registradas no ClinVar.

🧬 SLC25A4: GRCh38/hg38 4q32.1-35.2(chr4:157628420-189863176)x1 ()
🧬 SLC25A4: GRCh38/hg38 4q34.3-35.2(chr4:177853624-190036305)x1 ()
🧬 SLC25A4: GRCh37/hg19 4q32.1-35.2(chr4:161355371-190957473)x3 ()
🧬 SLC25A4: GRCh37/hg19 4q35.1-35.2(chr4:184213971-190957473)x1 ()
🧬 SLC25A4: NM_001151.4(SLC25A4):c.238C>T (p.Arg80Cys) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 5 variantes classificadas pelo ClinVar.

5
Patogênica (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
NUBPL: NM_025152.3(NUBPL):c.2T>C (p.Met1Thr) [Conflicting classifications of pathogenicity]
MTFMT: NM_139242.4(MTFMT):c.1100_1101del (p.Phe367fs) [Pathogenic/Likely pathogenic]
SERAC1: NM_032861.4(SERAC1):c.21C>A (p.Cys7Ter) [Likely pathogenic]
RMND1: NM_017909.4(RMND1):c.713A>G (p.Asn238Ser) [Pathogenic]
MTO1: NM_012123.4(MTO1):c.1282G>A (p.Ala428Thr) [Pathogenic/Likely pathogenic]

Vias biológicas (Reactome)

65 vias biológicas associadas aos genes desta condição.

Mitochondrial protein import Mitochondrial Uncoupling Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane Mitochondrial translation initiation Mitochondrial translation elongation Mitochondrial translation termination Mitochondrial ribosome-associated quality control Regulation of CDH11 Expression and Function Regulation of CDH11 gene transcription Intracellular oxygen transport Mitochondrial unfolded protein response (UPRmt) NADE modulates death signalling Activation of BIM and translocation to mitochondria Activation of caspases through apoptosome-mediated cleavage Ubiquinol biosynthesis Export of Viral Ribonucleoproteins from Nucleus NEP/NS2 Interacts with the Cellular Export Machinery Respiratory electron transport Complex I biogenesis Mitochondrial protein degradation Complex IV assembly Binding of TCF/LEF:CTNNB1 to target gene promoters Aryl hydrocarbon receptor signalling Ribosomal scanning and start codon recognition Translation initiation complex formation Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S GTP hydrolysis and joining of the 60S ribosomal subunit Regulation of NPAS4 gene expression Mechanical load activates signaling by PIEZO1 and integrins in osteocytes tRNA modification in the mitochondrion TP53 Regulates Metabolic Genes Cytoprotection by HMOX1 Mitochondrial tRNA aminoacylation Synthesis of wybutosine at G37 of tRNA(Phe) Interconversion of nucleotide di- and triphosphates Degradation of cysteine and homocysteine Detoxification of Reactive Oxygen Species tRNA processing in the mitochondrion rRNA processing in the mitochondrion Formation of ATP by chemiosmotic coupling Cristae formation Complex III assembly Neddylation Antigen processing: Ubiquitination & Proteasome degradation Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol alpha-linolenic acid (ALA) metabolism Beta-oxidation of pristanoyl-CoA Beta-oxidation of very long chain fatty acids Peroxisomal protein import TYSND1 cleaves peroxisomal proteins tRNA modification in the nucleus and cytosol Purine salvage Azathioprine ADME Mitochondrial RNA degradation Mitochondrial mRNA modification RHOG GTPase cycle HARS2 histidine + tRNA(His) + ATP => His-tRNA(His) + AMP + pyrophosphate Strand-asynchronous mitochondrial DNA replication Transcriptional activation of mitochondrial biogenesis Citric acid cycle (TCA cycle) Processing of SMDT1 Heme biosynthesis rRNA modification in the mitochondrion

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 21
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença da fosforilação oxidativa mitocondrial

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

4 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Iron overload damages mitochondria and induces metabolic rewiring of hematopoietic stem cells towards glycolysis.

Blood2026 Mar 24

Iron is an essential element for most cellular processes and recent evidence highlighted its role in regulating the function of hematopoietic stem cells (HSCs). Abnormal iron levels impact HSC quiescence and self-renewal, however, the mechanism by which iron overload (IO) influences HSC function is still unknown. Here, we show that intracellular IO impairs mitochondrial fitness and bioenergetics, inducing metabolic rewiring. In thalassemic mice, as a model of chronic IO, HSCs accumulate mitochondria with elevated reactive oxygen species (mtROS), low membrane potential and reduced oxidative phosphorylation (OXPHOS). Mitochondrial defects are confirmed in other two models of IO, sickle cell disease and iron-loaded wild-type mice, and in vivo iron reduction rescues HSC mitochondria. IO HSCs are highly proliferating and in presence of damaged mitochondria rely on glycolysis for energy production. Notably, restoration of mitochondrial function by targeting in vivo mtROS improved the quiescence and self-renewal of IO HSCs. Our results unravel the critical interplay between iron, ROS and mitochondrial activity in HSCs, revealing that IO shapes HSC metabolic programs.

#2

Mitochondrial stress as a conceptual interface between bacterial infection and post-infectious metabolic disease.

Frontiers in cellular and infection microbiology2026

Mitochondria are central hubs integrating cellular bioenergetics, redox balance, innate immune signaling, and metabolic homeostasis. During bacterial infections, these organelles are recurrent targets of pathogen-derived toxins, secreted effectors, and host inflammatory mediators, leading to a state broadly defined as mitochondrial stress. This stress encompasses alterations in oxidative phosphorylation, mitochondrial dynamics, calcium handling, reactive oxygen species (ROS) production, and activation or disruption of mitochondrial quality control pathways such as mitophagy. In this perspective, we propose mitochondrial stress as a conceptual framework linking bacterial infection and post-infectious metabolic disease. Using enteric bacterial pathogens such as Salmonella enterica serovars Typhimurium and Typhi, together with Vibrio parahaemolyticus, as conceptual models, we synthesize current evidence showing how distinct bacterial strategies converge on mitochondrial dysfunction and immunometabolic reprogramming of host cells. We argue that, while mitochondrial stress responses may initially support antimicrobial defense, their incomplete resolution may contribute to long-lasting metabolic and inflammatory alterations in epithelial, immune, and metabolic tissues. Persistent mitochondrial dysfunction may contribute to insulin resistance, chronic inflammation, and increased susceptibility to metabolic disease after infection. By framing mitochondrial stress as a central integrator of infection and metabolism, this perspective highlights key knowledge gaps and identifies mitochondria-centered pathways as potential targets to prevent or mitigate post-infectious metabolic sequelae.

#3

DNA2 acts as a brake on β cell insulin hypersecretion and diet-induced metabolic dysfunction.

Frontiers in cell and developmental biology2026

DNA replication helicase/nuclease 2 (DNA2) is an evolutionarily conserved nuclease-helicase with known role in maintaining nuclear genome stability. However, its potential involvement in metabolic regulation and disease remains unclear. This study investigates the role of DNA2 in pancreatic β cell physiology and diabetes pathogenesis. β cell-specific DNA2 knockout mice (DNA2INS2-/-) were generated and fed either a chow diet (CD) or high-fat diet (HFD). Metabolic phenotyping, insulin secretion assays, transcriptomic profiling, mitochondrial function analysis, and ultrastructural imaging were performed. INS-1 cells were used to assess the functions of DNA2 in vitro through knockdown, overexpression and site-directed mutagenesis. DNA2INS2-/- mice exhibited normal metabolic profiles under CD, but developed severe hyperglycemia, hyperinsulinemia, insulin resistance, and ectopic lipid deposition upon HFD feeding. This phenotype was accompanied by increased β cell proliferation and glucose-stimulated insulin secretion. RNA sequencing revealed the dysregulation of mitochondrial regulatory genes in DNA2-deficient islets. Functional assays confirmed that DNA2 deletion enhanced mitochondrial ATP production and oxidative phosphorylation, whereas its overexpression suppressed mitochondrial activity. Domain-specific mutagenesis demonstrated that both nuclease and helicase activities are essential for DNA2-mediated metabolic regulation. Our findings identify DNA2 as a negative regulator of mitochondrial bioenergetics and insulin secretion in β cells. By limiting mitochondrial activity, DNA2 serves as a rheostat that prevents β cell overactivation during metabolic stress, thereby preserving systemic glucose homeostasis.

#4

Bioenergetic impairment in schizophrenia: role of mitochondrial signaling in synaptic dysfunction - a systematic review.

Frontiers in cell and developmental biology2026

Mitochondrial dysfunction represents a critical pathophysiological mechanism in schizophrenia, potentially linking bioenergetic impairment to synaptic dysfunction and cognitive deficits. Converging evidence suggests that deficits in oxidative phosphorylation may drive the synaptic pathology contributing to treatment-resistant cognitive and negative symptoms. To systematically review the evidence linking mitochondrial bioenergetic dysfunction to synaptic impairment in schizophrenia, examining structural, functional, and molecular mechanisms across multiple methodological approaches. Following PRISMA guidelines, we searched PubMed/MEDLINE, Embase, PsycINFO, and Web of Science from 2000 to 2025 for original research studies investigating mitochondrial function and synaptic dysfunction in schizophrenia. Two independent reviewers screened 2,224 articles, with 29 studies meeting inclusion criteria. Quality was assessed using the Newcastle-Ottawa Scale (median score 7/9). Twenty-nine studies representing 2,847 participants demonstrated consistent mitochondrial dysfunction across postmortem (n = 10), neuroimaging (n = 8), and molecular/cellular (n = 11) investigations. Postmortem studies revealed reduced complex I (18%-35%) and complex IV activity (22%-28%) in prefrontal cortex, with concurrent synaptic density reductions (27%). Neuroimaging studies demonstrated 20%-22% reductions in ATP synthesis rates correlating with cognitive deficits (r = 0.48) and negative symptoms (r = -0.42). First-episode antipsychotic-naïve patients exhibited comparable bioenergetic abnormalities, indicating primary pathophysiology rather than medication effects. Molecular studies identified impaired calcium homeostasis, oxidative stress (27%-35% glutathione reductions in synaptic compartments), and novel pseudogene regulatory mechanisms perpetuating complex I deficits. Peripheral biomarkers including platelet complex I activity and cell-free mitochondrial DNA showed disease specificity and correlation with cognitive impairment. Substantial methodological heterogeneity precluded meta-analysis but provided complementary evidence across analytical levels. Mitochondrial bioenergetic impairment represents a core, potentially modifiable pathophysiological mechanism driving synaptic dysfunction in schizophrenia. Regional specificity (prefrontal cortex, hippocampus) and cell-type selectivity (pyramidal neurons) provide mechanistic insights into cognitive symptom profiles. Early presence and progressive worsening suggest critical intervention windows. Mitochondrial-targeted therapies merit investigation as novel approaches for treatment-resistant cognitive and negative symptoms.

#5

Metabolic dysfunction and mitochondrial failure in Alzheimer's disease: integrating pathophysiology, clinical evidence and emerging interventions.

Frontiers in neurology2026

Alzheimer's disease (AD) is a gradual and irreversible decline in the brain's ability to function which is not only signified by amyloid-beta plaques and neurofibrillary tangles but also by and metabolic and mitochondrial changes that have a negative impact on the classical neuropathological hallmarks. It is becoming increasingly clear that the central roles in the process of synaptic dysfunction, neuronal death and cognitive decline are played by the brain's impaired glucose utilization, insulin resistance, lipid metabolism alterations, and energy homeostasis disruption. Mitochondrial dysfunctions in AD comprising of oxidative phosphorylation defects, ATP production decrease, reactive oxygen species generation over and above the normal level, poor mitochondrial dynamics, and vacuolar-type H+-ATPase-mediated cell death are the factors that further worsen the situation and hence speed up the process of neuronal death and eventually, disease progression. The metabolic and mitochondrial disturbances have a two-way relationship with amyloid-beta and tau pathology, neuroinflammation, and oxidative stress, thus creating a self-sustaining cycle of neurodegeneration. Besides, clinical and neuroimaging studies, fluorodeoxyglucose positron emission tomography, cerebrospinal fluid biomarkers, and peripheral metabolic profiling all support the notion that metabolic impairment is an early and clinically relevant feature of AD very convincingly. Thus, the attention of the scientific community has turned more and more toward the approaches that use the metabolic and mitochondrial pathways as their target. The new treatments are coming, including insulin sensitizers, ketogenic and Mediterranean diets, mitochondrial-targeted antioxidants, exercise, metabolic modulators, and new drugs, all aimed at bringing back equilibrium to bioenergetics and letting neurons live longer. In this review, we have considered the current mechanistic insights, clinical evidence, and therapeutic advances related to metabolic dysfunction and mitochondrial failure in AD together and their potential as early biomarkers and modifiable targets for disease prevention and treatment that are highlighted.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1 artigos no totalmostrando 200

2026

Iron overload damages mitochondria and induces metabolic rewiring of hematopoietic stem cells towards glycolysis.

Blood
2026

Stress-induced OMA1-mediated cleavage of AIFM1 suppresses cell growth by controlling mitochondrial OXPHOS activity.

The EMBO journal
2026

Therapeutic potential of Qihuang Biwen Formula and its bioactive compounds for the treatment of ulcerative colitis in Drosophila and mice.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

Targeting the oxidative stress-neuroinflammation axis: the mechanism of arctigenin's broad-spectrum analgesia with limited side effects.

Frontiers in immunology
2026

Integrating Multi-Omics Data to Uncover Causal Links Between Mitochondria-Related Genes and Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Study.

International journal of chronic obstructive pulmonary disease
2026

Mitochondrial stress as a conceptual interface between bacterial infection and post-infectious metabolic disease.

Frontiers in cellular and infection microbiology
2026

Expanding the Phenotype of TUFM-Related Combined Oxidative Phosphorylation Deficiency 4.

American journal of medical genetics. Part A
2026

HADHA in Cardiovascular Disease: From Mitochondrial Dysfunction to Therapeutic Targets.

Ageing research reviews
2026

Exercise and CD8+ T cells: mechanisms of immune modulation in antitumor responses.

Journal of molecular medicine (Berlin, Germany)
2026

DNA2 acts as a brake on β cell insulin hypersecretion and diet-induced metabolic dysfunction.

Frontiers in cell and developmental biology
2026

Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.

Journal of cachexia, sarcopenia and muscle
2026

Integrated molecular and clinical profiling of primary mitochondrial oxidative phosphorylation disorders in an Indian cohort: Insights from genetics, neuroimaging, and machine learning.

Mitochondrion
2026

Neurometabolic Substrate Utilization Governs Oxidative Phosphorylation Conductance in Cortex and Hippocampus.

Journal of neurophysiology
2026

Androgen receptor localisation and protein interactions provide insight into steroid mediated metabolic shifts in endocrine resistant breast cancer.

NPJ breast cancer
2026

Deficient Cardiolipin Remodelling Alters Muscle Fibre Composition and Neuromuscular Connectivity in Barth Syndrome.

Journal of cachexia, sarcopenia and muscle
2026

Chloroplast-Inspired Nanoassemblies for Ischemic Stroke Therapy: Cross-Kingdom Recoupling with Mitochondrial Metabolism.

ACS nano
2026

1β,6α-Dihydroxyeudesm-4(15)-ene Protects Against MPP+-Induced Cytotoxicity in SH-SY5Y Cells: An In Vitro Model of Parkinson's Disease.

Journal of medicinal food
2026

Ironing out COPD: ferroptosis-driven immune dysregulation, metabolic rewiring, and precision therapeutic opportunities.

Frontiers in immunology
2026

Bioenergetic impairment in schizophrenia: role of mitochondrial signaling in synaptic dysfunction - a systematic review.

Frontiers in cell and developmental biology
2026

Current perspectives on circadian regulation of mitochondrial dynamics in mood disorders and perioperative stress.

Frontiers in pharmacology
2026

Metabolic dysfunction and mitochondrial failure in Alzheimer's disease: integrating pathophysiology, clinical evidence and emerging interventions.

Frontiers in neurology
2026

Focused Ultrasound Stimulation on the Spleen Ameliorates DSS-Induced Neuroinflammation Through the Notch Signaling Pathway.

Ultrasound in medicine & biology
2026

Recent advances in polymeric nanoparticle-mediated drug delivery system across the blood-brain barrier in Alzheimer's disease.

Colloids and surfaces. B, Biointerfaces
2026

Transcription Factors in Type 2 Diabetes: Molecular Mechanisms of Insulin Resistance and β-Cell Dysfunction.

Current diabetes reviews
2026

Mitochondrial Iron Handling and Lipid Peroxidation as Drivers of Ferroptosis.

International journal of molecular sciences
2026

COG5 deficiency disrupts cellular copper homeostasis and underlies the impaired mitochondrial OXPHOS function.

PLoS genetics
2026

Survival After Massive Potassium Cyanide Ingestion Without Antidote in a Tertiary Care Setting.

Cureus
2026

Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease.

Neurology. Genetics
2026

Molecular mechanism underlying the specific RNA recognition of mitochondrial helicase DDX28 and its critical role in mitoribosomal biogenesis.

Structure (London, England : 1993)
2026

Molecular and immunological heterogeneity of eosinophilic esophagitis: Insights and subtyping.

PloS one
2026

PPRC1 is a prognostic biomarker and key regulator of mitochondrial oxidative phosphorylation in multiple myeloma.

Annals of medicine
2026

Astrocytic Mitochondria Transplantation Rescues Neuron Loss and Dendritic Injuries in Acute Cerebral Ischemic Stroke Mouse Model by Flexibly Regulating Mitochondria Dynamics.

Annals of neurology
2026

Glycosomal Phosphoenolpyruvate Carboxykinase CRISPR/Cas9-Deletion and Its Role in Trypanosoma cruzi Metacyclogenesis and Infectivity in Mammalian Host.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Cardiometabolic adaptations in the cave nectar bat Eonycteris spelaea.

Communications biology
2026

Alizarin induces a multidirectional mechanism of anti-cancer action in cervical cancer and prostate cancer cells.

Scientific reports
2026

Bioenergetic Profiling of Lymphocytes in Patients With Visceral Leishmaniasis (VL) and Post Kala-Azar Dermal Leishmaniasis (PKDL).

Parasite immunology
2026

The goal attainment scale in primary mitochondrial disease: Construct validity and lessons learned from a randomized controlled trial.

Molecular genetics and metabolism
2026

Proteomic mapping of Rosa damascena nanovesicles reveals plastid mitochondrial metabolic convergence and antimicrobial peptides.

Plant signaling & behavior
2026

Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer.

Biochimica et biophysica acta. Reviews on cancer
2026

Transcriptomic analysis reveals synaptic dysregulation and mitochondrial dysfunction in autism spectrum disorder.

Brain, behavior, & immunity - health
2026

Iron, arginine, and redox metabolism in peripheral blood mononuclear cells distinguishes sickle cell disease and pulmonary hypertension.

HemaSphere
2026

Modulation of KATP channels by diazoxide preserves mitochondrial function and barrier integrity under staurosporine-induced epithelial stress.

British journal of pharmacology
2026

Sigma-1 receptor regulates HIV-1 and methamphetamine-induced endothelial/pericyte barrier impairment via strain-specific inflammatory responses and mitochondrial dysregulation.

Journal of neuroinflammation
2026

Mitochondrial and Ribosomal Stress Underlying Pronuclear Envelope Breakdown Failure: Insights From Single-Cell Transcriptomics in Human Zygotes.

Molecular reproduction and development
2026

Molecular Effect of Tobacco on Genetic, Epigenetic, and Metabolic Pathways During Cancer Progression.

Cureus
2026

Transcriptomic and proteomic insights into progressive myoclonus epilepsy, EPM1.

Disease models & mechanisms
2026

Tofacitinib repairs inflammation and mitochondrial dysregulation in GM-CSF-reprogrammed RA macrophages.

Cellular & molecular immunology
2026

Mitochondrial dysfunction: a new target for traditional Chinese medicine in the treatment of chronic heart failure.

Chinese journal of natural medicines
2026

Acox1 induces lipid peroxidation and metabolic shifting to promote PASMCs proliferation in hypoxia-induced pulmonary hypertension.

Free radical biology & medicine
2026

Pharmacological stabilization of hypoxia-inducible factor 1-α dampens the interferon response and promotes glycolysis in Aicardi-Goutières syndrome.

Nature communications
2026

Early-activated extracellular matrix proteins shape the metabolic and spatial dynamics of the kidney fibrotic microenvironment.

Nature metabolism
2026

Mitochondrial Pyruvate Metabolism Controls Alveolar Stem Cell Fate and Inflammatory Balance.

Inflammation
2026

Mitochondrial complex assembly in epilepsy of primary mitochondrial disease origin.

Seizure
2026

Fumarate loss destabilizes mitochondria and activates cGAS-STING in OLP.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2026

Loss of Splicing Homeostasis as a Hallmark of Aging.

Molecular and cellular biology
2026

Expanding the genotypic spectrum of combined oxidative phosphorylation deficiency 54.

Neurogenetics
2026

Loss of Early Growth Response Protein 1 in the Liver Leads to Hepatic Lipid Accumulation Driven by an Imbalance Between Fatty Acid β-Oxidation and Oxidative Phosphorylation.

Gastro hep advances
2026

Discovery of Genes Related to Cuproptosis and Mitophagy to Improve Myocardial Infarction Diagnosis and Treatment.

Current gene therapy
2026

Beyond readthrough: ataluren restores mitochondrial function and reduces oxidative stress in FANCA-mutated cells via mTOR-DRP1 modulation.

Cell death discovery
2026

Deciphering the role of mitochondrial cytochrome C oxidase subunit 4 in cardiac health and disease.

Life sciences
2026

A case report of combined oxidative phosphorylation deficiency 35 (COXPD35) in Palestine caused by novel compound heterozygous TRIT1 variants.

Medicine
2026

α-synuclein preformed fibrils suppress cell cycle progression and glycolytic flux in glioblastoma cells.

Experimental cell research
2026

Transcriptomic analysis of cells following decreased mitochondrial DNA-copy number reveals compensatory mechanisms in mitochondrial DNA replication and cellular energetics.

Experimental cell research
2026

Multilevel impairment of mitochondrial respiration with sex-specific signatures in inclusion body myositis.

bioRxiv : the preprint server for biology
2026

Clemastine Restores Myelination Protein Expression in S16 Schwann Cells by Enhancing AMPK Activation and Reducing H2O2-Induced Oxidative Stress.

Biomolecules & therapeutics
2026

Mesenchymal Stromal Cells and Extracellular Vesicles: A Novel Therapeutic Paradigm for Mitochondrial Dysfunctions.

International journal of molecular sciences
2026

Therapeutic Potential of Deferiprone-Resveratrol Hybrid (DFP-RVT) Against Hepatic Iron Overload in β-Thalassemia Mice: A Proteomic Analysis.

Biomolecules
2026

Mitochondrial Dysfunctions in Human Primary Coenzyme Q10 Deficiencies.

Biomolecules
2026

The Role of Cold-Inducible RNA-Binding Protein (CIRP) in Neurological Disorders.

Brain sciences
2026

Potential Biological Processes Related to Brain SLC13A5 Across the Lifespan: Weighted Gene Co-Expression Network Analysis from Large Human Transcriptomic Data.

Brain sciences
2026

Bmal1 regulates thermogenic function by modulation of lipolytic and OXPHOS gene expression in male mice brown adipocytes.

Endocrinology
2026

Role of mitochondria in neuronal function and survival in the enteric and central nervous systems.

Cellular and molecular life sciences : CMLS
2026

Engineering Mitochondrial Biogenesis in iPSC-CMs: CRISPR-Guided Approaches for Advanced Cardiomyocyte Development.

Journal of cardiovascular development and disease
2026

Mitochondrial Resilience in Glaucoma: Targeting NAD+ Metabolism and Oxidative Stress in Retinal Ganglion Cell Degeneration with Nicotinamide Riboside and Berberine: Preliminary Clinical Evidence.

Diseases (Basel, Switzerland)
2026

TCA cycle intermediates as an adjunct strategy for human iPSC-derived cardiomyocyte maturation.

BBA advances
2026

CD4+T cell metabolic reprogramming as therapeutic targets in neurodegenerative diseases.

Molecular brain
2026

Proline-Mediated Inhibition of ATPIF1-mTOR Signaling Alleviates Radiation-Induced Macrophage Polarization and Colon Inflammation.

Inflammation
2026

AMPK Deficiency Induces Corneal Epithelial Barrier Dysfunction by Modulating Energy Homeostasis.

Investigative ophthalmology & visual science
2026

Mitochondrial abnormalities in idiopathic inflammatory myopathies.

Clinical and experimental rheumatology
2026

Unraveling the molecular mechanisms in severe Alzheimer's disease based on transcriptomic data using next generation knowledge discovery methods.

Pakistan journal of medical sciences
2026

Hypoxia-induced LGALS8-AS1 sustains oxidative phosphorylation to drive breast cancer progression.

Biochemical and biophysical research communications
2026

Repair of Corneal Epithelial Defects.

Progress in molecular and subcellular biology
2026

Machine learning-driven identification of shared and disease-specific mitochondria-related genes in COPD, NSCLC, and NSCLC with COPD.

iScience
2026

Comparative phenotypic and molecular profiling of replicative and chemically-induced senescence in articular chondrocytes.

Cell death discovery
2026

Hypertrophic cardiomyopathy as a novel phenotypic feature of NSUN3-related mitochondrial disease: a case report with review of the literature.

Journal of pediatric endocrinology & metabolism : JPEM
2026

Mitochondrial respiration and hydrogen peroxide production rate in right atrial tissues from obese diabetic patients.

Experimental physiology
2026

Variants in MTNAP1 underlie a neurodegenerative disorder by impairing mitochondrial stability.

NPJ genomic medicine
2026

Ergothioneine rescues obesity-induced testicular dysfunction via dual restoration of steroidogenesis and mitochondrial redox homeostasis.

Redox biology
2026

Dietary chromium picolinate-promoted oxidative phosphorylation may be a potential mean to improve hypoxia tolerance of juvenile grass carp (Ctenopharyngodon idella).

Animal nutrition (Zhongguo xu mu shou yi xue hui)
2026

Unraveling Network Pharmacology-Based Therapeutics of Anthranilate Sulfonamides via Sirtuins/FOXO3a Cascade in Alzheimer's Disease.

Journal of neurochemistry
2025

Role of CR6-Interacting Factor 1 (Crif1) in Cardiac Mitochondrial Structure and Stress-Induced Functional Decline.

Korean circulation journal
2026

Harnessing Anthocyanins to Mitigate Inflammation, Dysbiosis, and Aging in the Gastrointestinal Tract.

ACS pharmacology & translational science
2026

Senegenin attenuates LPS-induced neuroinflammation and microglial cell death via Akt phosphorylation and suppression of cGAS-STING-NLRP3 signaling: Network pharmacology and experimental validation.

Journal of ethnopharmacology
2026

Tubular EZH2 promotes acute kidney injury by Inhibiting SDHC-mediated mitochondrial function.

Free radical biology & medicine
2026

Mitochondrial dysfunction and AMPK-associated metabolic reprogramming in zebrafish exposed to fluorinated liquid crystal monomers.

Ecotoxicology and environmental safety
2026

The succinate prodrug NV354 prevents brain lesions and late-stage motor dysfunction in mitochondrial complex I deficiency.

iScience
2026

Mitochondrial Metabolism in Neutrophils: Emerging Roles in Inflammatory Skin Diseases.

The British journal of dermatology
2026

TGFβ-activated PDHB promotes mitochondrial pyruvate metabolism and contributes to human endoderm differentiation via ATP-dependent BRG1.

Nature communications
2026

Enhanced CHI3L1 promotes macrophage activation in persistent inflammatory events of ulcerative interstitial cystitis.

Frontiers in immunology
2026

A novel tRNASer(AGY) 12244G > a variant impairs mitochondrial function and presents with classical MELAS phenotype.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Hydrogel-based mitochondrial therapies: A new frontier in disease treatment.

Biomaterials
2026

Benefits of oral nitrite supplementation on mitochondrial respiration and physical function in older adults.

The journals of gerontology. Series A, Biological sciences and medical sciences
2026

FASN-mediated metabolic reprogramming drives CD4+ T cell hyperactivation in Sjögren's syndrome via fatty acid oxidation-dependent oxidative phosphorylation.

Arthritis research & therapy
2026

Immunometabolism Reframes Alzheimer's Disease: From Systemic Dysmetabolism to Glial Rewiring.

Cellular and molecular neurobiology
2026

Mechanisms and disease relevance of mitochondrial translation in humans.

Nature reviews. Molecular cell biology
2026

Spatiotemporal transcriptomic profiling reveals upregulation of glycolysis pathway genes before overt tauopathy in the PS19 mouse model.

Experimental & molecular medicine
2026

Progression of peripheral blood mononuclear cell mitochondrial function during the early phase of sepsis in intensive care unit patients.

Scientific reports
2026

STARD10 regulates human pancreatic β cell differentiation and triglyceride metabolism.

Stem cell reports
2026

Post‑translational modifications in diabetic kidney disease (Review).

International journal of molecular medicine
2026

Divergent mitochondrial and metabolic adaptations shape selective vulnerability in ALS.

bioRxiv : the preprint server for biology
2026

Molecular and Neuroimaging Correlates of Bipolar Disorder: Linking Inflammation, Mitochondria, and Brain Circuitry.

International journal of molecular sciences
2026

Colonic spatial single-cell proteomics and murine models link mitochondrial dysfunction to dimeric IgA-secreting plasma cell deficiency in Crohn's disease.

Nature communications
2026

Ginsenoside Rh4 activates AMPK and alleviates NFκB-mediated inflammation in hyperlipidemic hepatopathy.

Free radical biology & medicine
2026

Integrative metabolomics and network pharmacology reveal the therapeutic mechanisms of Inonotus hispidus (Bull.) P. Karst. extract against primary dysmenorrhea.

The Journal of steroid biochemistry and molecular biology
2026

ROMO1 is involved in airway mucus hypersecretion in COPD through the mitochondrial ROS-STAT6 pathway.

Respiratory research
2026

Lactiplantibacillus plantarum GUANKE ameliorates influenza a virus-induced inflammation and lung barrier dysfunction through enhancing mitophagy and improving oxidative phosphorylation.

Cellular and molecular life sciences : CMLS
2026

Optic neuropathy arising from the synergy between YARS2 and mitochondrial COX1 mutations.

Journal of genetics and genomics = Yi chuan xue bao
2026

Src-mediated PHB2 phosphorylation disrupts mitochondrial cristae through cardiolipin dissociation in hepatocellular carcinoma.

Redox biology
2026

Distinct roles of PINK1 autophosphorylation in neonatal hypoxia with or without convulsions.

International immunopharmacology
2026

MTFP1 drives pancreatic cancer liver metastatic colonisation by regulating mitochondrial metabolism reprogramming.

Gut
2026

Polymer of methyl malonic acid suppress inflammation by downregulating IL-2 through ROS overproduction.

bioRxiv : the preprint server for biology
2026

Honokiol protects against acute pancreatitis by activating SIRT3 to restore mitochondrial oxidative phosphorylation and alleviate hyperacetylation.

Journal of integrative medicine
2026

Hydroxychloroquine alleviates renal fibrosis by modulating dendritic cells glycolipid metabolism and its crosstalk with renal tubular epithelial cells.

European journal of pharmacology
2026

D-ribose-induced cytotoxicity in K562 cells: RBKS-dependent disruption of copper homeostasis and mitochondrial function.

Free radical biology & medicine
2026

Paenibacillus polymyxa K17 Controls Leaf Spot of Tea Plant by Impairing Fungal Cellular Structure and Energy Metabolism.

Journal of agricultural and food chemistry
2026

Screening strategy using a filamentous fungus model to repurpose drugs for mitochondrial complex I deficiencies.

Life sciences
2026

Trans-activator of transcription-pre-B-cell leukemia transcription factor 1 alleviates Alzheimer's disease by reducing neuronal insulin resistance and restoring energy homeostasis.

Neural regeneration research
2026

Proteomic profiles in inclusion body myositis and polymyositis with mitochondrial pathology.

Acta neuropathologica communications
2026

Mitochondrial DNA mutations and intercellular mitochondrial transfer in cancer: mechanisms, biological effects, and clinical potential.

Biomarker research
2026

Cardiac mitochondrial proteome of lean, healthy Ossabaw minipigs with predisposition to metabolic syndrome versus that of Göttingen minipigs.

American journal of physiology. Heart and circulatory physiology
2026

Proteomics landscape of early T-cell precursor acute lymphoblastic leukemia reveals deficient oxidative phosphorylation signatures.

Cell reports. Medicine
2026

The Ketogenic Diet in the Neonatal Intensive Care Setting: The Case of a Preterm Newborn With Mitochondrial DNA Depletion Syndrome Type 13 (MTDPS13).

Case reports in genetics
2026

Targeting TFAM K76 acetylation attenuates mitochondrial dysfunction and kidney injury in diabetic kidney disease.

Cardiovascular diabetology
2026

Chronic NH4Cl loading improves glucose tolerance without modifying insulin sensitivity in mice.

Scientific reports
2026

Psoralidin, a main compound in Psoraleae Fructus, induces hepatotoxicity by impeding lipid oxidative catabolism and aggravating lipid accumulation in mice.

Chinese medicine
2026

Effects of exercise training on oxidative phosphorylation-related genes in a diabetic heart via microarray analysis.

BMC cardiovascular disorders
2026

Mapping the causal chain from genetic risk variants to lipid dysmetabolism in Parkinson's disease.

Brain : a journal of neurology
2026

Neuropeptide S Protects Dopaminergic Neurons in a Paraquat-Induced Parkinson's Model Using SH-SY5Y Cells.

Molecular neurobiology
2026

Downregulated ECHS1 and HADH-mediated fatty acid β-oxidation contributes to mitochondrial dysfunction in salivary glands of Sjögren's syndrome.

Journal of translational autoimmunity
2025

Mechanisms of microRNA trafficking to mitochondria in the heart.

Current opinion in physiology
2026

Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis.

European journal of medical research
2026

JNK1 mediates serine phosphorylation of STAT3 in response to fatty acids released by lipolysis.

Journal of lipid research
2026

Clinical and biochemical footprints of primary mitochondrial disorders: proposed nosology.

Molecular genetics and metabolism
2026

Phthalate Metabolite, Mono(2-Ethyl-5-Hydroxyhexyl) Phthalate (MEHHP), Promotes Uterine-Fibroid-Associated Phenotypes in Myometrial Stem Cell-Derived 3D Organoids.

Environmental toxicology
2026

DNA methylation-mediated alterations in Copper(I/II) redox equilibrium underlie lead-induced neurotoxicity.

Environmental pollution (Barking, Essex : 1987)
2026

The possible mechanism of L-arginine improved intestinal barrier health in grass carp (Ctenopharyngodon idella): via suppressing apoptosis and enhancing mitochondria-endoplasmic reticulum crosstalk.

Free radical biology & medicine
2026

A novel metabolic gene signature induced by Di-(2-ethylhexyl) phthalate and Mono-(2-ethylhexyl) phthalate exposure predicts prognosis in breast cancer: An integrative bioinformatics and experimental study.

Ecotoxicology and environmental safety
2025

Multi-Omics Elucidation of Edulinine's Intervention Mechanism in Hypertensive Rats.

Current issues in molecular biology
2026

SDHA Deficiency in Hepatocellular Carcinoma Promotes Tumor Progression through Succinate-Induced M2 Macrophage Polarization.

Oncology research
2026

Single-Cell RNA Sequencing and Network Pharmacology Reveal the Potential Role of Oxidative Phosphorylation Inactivation in Diagnosing and Treating Chronic Tendon Injuries.

The journal of gene medicine
2025

The aggregate proteome of Caenorhabditis elegans mitochondria implicates shared mechanisms of aging and Alzheimer's disease.

Frontiers in aging neuroscience
2026

Vacuole and mitochondria patch (vCLAMP) protein Mcp1 reduces the pathogenesis of Candida albicans by impeding the function of Cap1-mediated oxidative stress response.

BMC microbiology
2026

Sinomenine inhibits oxidative stress to attenuate Alzheimer's disease pathology via α7 nicotinic acetylcholine receptor.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

Effects of Tributyltin Chloride on Human Neuronal Differentiation and Mice Brain Development.

Environmental toxicology
2026

Cystinosis and Cellular Energy Failure: Mitochondria at the Crossroads.

International journal of molecular sciences
2026

Mitochondrial DNA Instability and Neuroinflammation: Connecting the Dots Between Base Excision Repair and Neurodegenerative Disease.

Genes
2026

The LncRNA11-hnRNPA1 functional axis maintains adipose tissue metabolic homeostasis by promoting mitochondrial respiration and lipid utilization.

International journal of biological macromolecules
2026

In vitro investigation of miR-206-3p-loaded extracellular vesicles as modulators of Aβ-induced neurodegeneration.

Biochemical and biophysical research communications
2026

Ex Vivo Human Colonic Explants Identify Metabolic Alterations and Cytokine Dysregulation in Ulcerative Colitis: A Pilot Study.

Digestive diseases and sciences
2026

Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases.

Pharmacological reports : PR
2026

Sensitivity of primary mitochondrial disease fibroblasts to ferroptosis: The role of intracellular iron.

Mitochondrion
2026

Epigenetic alterations of AKT1 orchestrate a metabolic reprogramming in advanced lipedema: translational insights from an integrated multi-omics study.

Journal of translational medicine
2026

Deficient mitochondrial tRNA modifications arising from TRMU mutation led to the liver-specific failure.

The Journal of biological chemistry
2026

CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.

Cell reports. Medicine
2026

Amine-modified polystyrene particles induce surface chemistry-driven immunotoxicity in microglia: Protective effects of trolox.

Ecotoxicology and environmental safety
2026

MPC1 deficiency promotes melanoma progression via Wnt/β-catenin signaling.

Biochemical and biophysical research communications
2025

Glucose and Oxygen Metabolism Coordinate Human Cortical Developmental Decisions.

bioRxiv : the preprint server for biology
2025

NDUFS4, a mitochondrial complex I subunit, is essential for T-cell metabolic fitness and immune function.

Frontiers in immunology
2026

Impact of Toll/Interleukin-1 Receptor Domain Protein C on Mesenchymal Stem Cells Mitochondrial Protein Expression: A Proteomic Study.

Current molecular medicine
2026

The Interplay between PKC and ELAV4 in the CNS: An Emerging Therapeutic Axis for Dementia Management.

CNS & neurological disorders drug targets
2026

Itaconate and its derivatives ameliorate autoimmunity by suppressing Th17 cells via regulating mitophagy.

Cell communication and signaling : CCS
2026

Shikonin attenuates diabetic Parkinsonian neuronal injury by facilitating p53/SLC25A28-mediated iron shuttling.

Biochemical pharmacology
2026

Isocucurbitacin B targets STAT3 to induce ferroptosis and promote anti-PD1 immunotherapy responses in breast cancer.

International journal of surgery (London, England)
2026

Nuclear MBL-1 modulates mitochondrial morphology through carnitine palmitoyltransferase in Caenorhabditis elegans with toxic trinucleotide repeats.

Proceedings of the National Academy of Sciences of the United States of America
2026

Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine.

Cancer
2025

Unraveling the role of mitochondrial dysfunction in diabetic kidney disease: insights and interventions.

Frontiers in pharmacology
2026

Mitigating Dexamethasone-Induced Muscle Wasting and Mitochondrial Impairment in Mice on a High-Fat and High-Sucrose Diet With Peanut Sprout Extract.

Food science & nutrition
2026

The herbal compound miltirone from Salvia miltiorrhiza targets DJ-1 to induce mitophagic dysfunction and ROS-dependent hippo activation in gastric cancer.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

A New Combination Therapy Utilizing Mitochondria-Targeting Small-Molecule Ligands and Clinical Inhibitors against Melanoma.

ACS chemical biology
2026

Multiomics Reveals Mitochondrial and Metabolic Perturbations Underlying Cyclotriphosphazene-Induced Lung Injury.

Environment & health (Washington, D.C.)
2026

Constraint-based modelling of metabolic dysregulation in Gaucher disease: mitochondrial dysfunction and disrupted cholesterol homeostasis.

Orphanet journal of rare diseases
2026

A novel extracellular flux assay workflow uncovers impaired sciatic nerve mitochondrial respiration in diabetic db/db mice.

Cell communication and signaling : CCS
2026

CircRNA HIPK2-mediated metabolic reprogramming restores mitochondrial homeostasis in chondrocytes through the miR-206/Sirt3 signaling axis attenuating osteoarthritis-induced nociception.

Inflammopharmacology
2026

SARS-CoV-2 altered mitochondrial DNA methylation in Indian COVID-19 patients.

Scientific reports
2026

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.

Cell death discovery
2026

The Interplay Between Nurr1 and Mitochondrial Biogenesis: Implications for Neurodegenerative Therapy.

Molecular neurobiology
2025

Prokaryotic organelle mitochondria drive tumorigenesis: "the original sin".

Frontiers in oncology
2026

Deficiency of Microglial-Derived Spp1 Exacerbates Age-Related Memory Decline by Impairing Mitochondrial Complex I Function.

Aging cell
2026

Triclosan exacerbates post-myocardial infarction injury via Nur77 ubiquitination: Linking NTRK2/PGC-1α-mediated mitochondrial dysfunction to senescence and ferroptosis.

Redox biology
2026

Skeletal muscle transcriptional dysregulation of genes involved in senescence is associated with prognosis in severe heart failure.

Communications medicine
2026

Genetic and neuroanatomical correlates of bipolar disorder in high-risk youth.

BMJ mental health
2026

The myocardial ischemic cascade network and multi-target synergistic interventions: From molecular mechanisms to therapeutic innovations.

Biochemical pharmacology
2026

UQCRC1 deficiency impairs mitophagy via PINK1-dependent mechanisms in Parkinson's disease.

NPJ Parkinson's disease
2026

Brown adipocyte-derived SAA3-CPT1A axis regulates diet-induced thermogenesis and protects against obesity.

The Journal of nutritional biochemistry
2026

A transcriptomic and proteomic map of primary human cell types.

Nucleic acids research
2026

Sex-dependent differences in bioenergetics of young mouse brain microvasculature: implications for oxygen-glucose deprivation and reoxygenation injury.

American journal of physiology. Heart and circulatory physiology
2025

Mitochondrial Disorder in a Child With Brainstem Lesions Mimicking Thiamine Deficiency.

Cureus
2026

Purinosomes and mitochondria: Dynamic interactomes at the crossroads of metabolism, cell structure, and disease.

Pharmacological research
2026

Structural basis for late maturation steps of mitochondrial respiratory chain complex IV within the human respirasome.

Nature communications
2026

OX-LDL causes vascular endothelial injury by interfering with the CREB1-MDH1B-malate axis.

Free radical biology & medicine

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença da fosforilação oxidativa mitocondrial.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença da fosforilação oxidativa mitocondrial

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Iron overload damages mitochondria and induces metabolic rewiring of hematopoietic stem cells towards glycolysis.
    Blood· 2026· PMID 41878806mais citado
  2. Mitochondrial stress as a conceptual interface between bacterial infection and post-infectious metabolic disease.
    Frontiers in cellular and infection microbiology· 2026· PMID 41868147mais citado
  3. DNA2 acts as a brake on β cell insulin hypersecretion and diet-induced metabolic dysfunction.
    Frontiers in cell and developmental biology· 2026· PMID 41858776mais citado
  4. Bioenergetic impairment in schizophrenia: role of mitochondrial signaling in synaptic dysfunction - a systematic review.
    Frontiers in cell and developmental biology· 2026· PMID 41836300mais citado
  5. Metabolic dysfunction and mitochondrial failure in Alzheimer's disease: integrating pathophysiology, clinical evidence and emerging interventions.
    Frontiers in neurology· 2026· PMID 41835065mais citado
  6. Corn silk extract ameliorates cisplatin-induced cardiac injury by restoring mitochondrial function and suppressing ferroptosis.
    Food Funct· 2026· PMID 41989386recente
  7. Hypoxic microenvironment in cancer: role in metabolic reprogramming.
    Front Oncol· 2026· PMID 41988136recente
  8. Monophosphoryl lipid A boosts macrophage antimicrobial immunity by metabolically regulating source-specific ROS generation.
    Front Immunol· 2026· PMID 41983139recente
  9. Molecular insights into CRIP1 as an immunometabolic regulator revealed by CRIP1 knockout and single-cell transcriptomics.
    Front Immunol· 2026· PMID 41972184recente
  10. Loss of TRPV1 may shift capsaicin response from MAPK-CASC11-MYC protection to mitochondrial apoptosis in glioblastoma U87 cells.
    Int J Biol Macromol· 2026· PMID 41967549recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:223713(Orphanet)
  2. MONDO:0016387(MONDO)
  3. GARD:20546(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55786187(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença da fosforilação oxidativa mitocondrial
Compêndio · Raras BR

Doença da fosforilação oxidativa mitocondrial

ORPHA:223713 · MONDO:0016387
CID-11
MedGen
UMLS
C5679825
EuropePMC
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades